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SPLIT-COURSE HYPOFRACTIONATED RADIOTHERAPY FOR 
PALLIATION OF ADVANCED HEAD AND NECK SQUAMOUS 
CELL CARCINOMA 
Dr. Vishal Manik*, Prof. Dr. S. Shanmugakumar, Prof. Dr. N. V. 
Kalaiyarasi 
INTRODUCTION: A significant proportion of patients with head and 
neck squamous cell carcinoma (HNSCC) are unsuitable for radical 
treatment due to factors including tumour stage, performance status (PS) 
and co-morbidity. Palliative radiotherapy has a useful role in the control of 
local symptoms. 
AIM: To assess the local symptom control of advanced HNSCC treated 
with split course hypofractionated radiotherapy. Additionally, to assess the 
Quality of Life (QoL); the acute toxicity to the treatment and the immediate 
loco-regional response. 
MATERIALS AND METHODS: Thirty patients of very advanced 
HNSCC with PS of >2 were selected. All the patients after basic work up, 
were planned to receive initial course of 20Gy radiation (4Gy/ 5 fractions) 
followed by a two week gap and then re-assessment. All patients with 
absent or manageable toxicity were further treated with one more course 
of 20 Gy radiation. Symptom relief was assessed before and after each 
course of radiation. QoL was assessed using the EORTC QoL 
questionnaire, before and after radiotherapy. 
RESULTS: Out of the study population, 70% were males, 50% belonged 
to age group 61-70 years and all had a PS ≥3. Oropharynx (33.3%) was the 
commonest site with base of tongue (20%), the commonest subsite. Stage 
grouping was IVB in 56.67% with 46.67% having a N3 node and 
dysphagia (43.3%) at presentation. Only 3 patients could not complete the 
planned courses of RT. Good symptom relief was observed in 73.3%. 
Improvement in symptom scales was seen, however, functional and global 
health scores remained low. None had more than Grade 1-2 toxicity from 
first course. Grade 2 toxicity was seen in majority of patients after second 
course. Overall response rate was 100% with partial response (PR) in most 
cases. Median duration of response was 2 months post-treatment. 
CONCLUSION: Split course hypofractionated palliative RT is feasible in 
advanced HNSCC and allows for shorter treatment time with acceptable 
symptom relief. 
KEY WORDS: Split – course, Hypofractionation, Palliation, Advanced 
HNSCC 
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INTRODUCTION: 
Cancer, a disease which has perplexed many, doctors and patients alike 
is now one of the leading causes of death worldwide. Complex aetiology, 
genetic and molecular interplay, social and lifestyle factors, have been 
responsible for difficulties in diagnostics and treatment of this dreaded 
disease.  
 
1. Cancer Epidemiology: 
The specialized cancer wing of the World Health Organization, 
International Agency for Research on Cancer (IARC), released the 
latest data on cancer incidence, mortality, and prevalence worldwide in 
December 2013. Their online database, GLOBOCAN 2012, revealed 
the most recent estimates of incidence and prevalence rates of different 
types of cancer. It estimated that 14.1 million new cases of cancer and 
8.2 million cancer-related deaths occurred in 2012, compared to 12.7 
million and 7.6 million, respectively, in 2008.[1] Prevalence estimates 
for 2012 showed that there were 32.6 million people surviving with a 
cancer diagnosed in the previous five years.[2] Over half of all cancer 
incidence (56.8%) and cancer mortality (64.9%) in 2012 occurred in the 
developing nations. Cancer and related issues have always occupied a 
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distinctive stature in the Indian oncologic scenario. With westernisation 
of our culture, habits and lifestyle practices, Indian population has seen 
an upward trend in the incidence of cancer over the past two decades. In 
India, an estimated 5.5 lac people died of cancer in 2010. [3] According 
to a recent Government of India study, 7% of all deaths annually, occur 
owing to cancer. Though the incidence has gone up, the mortality rates 
have not reduced either thus increasing the overall cancer burden over 
the society. Further, in the recent years, figures have shown a gradual 
increase in the incidence among younger age groups due to use of some 
form of tobacco among school children in age group of 10-15 years. [4]  
 
2. Head & Neck Cancer Statistics: 
All over the world, head and neck cancers account for more than 
550,000 cases annually. [5] Overall, 57.5% of global head and neck 
cancers occur in Asia especially in India, for both sexes. [6] In the 
developed countries, head and neck squamous cell carcinoma (HNSCC) 
account for only 3% of all malignancies. [7] Oral cavity and tongue 
cancers are more common in India while pharyngeal and laryngeal 
cancers are more common in other populations. [8] Lip and pharynx 
were found to be the commonest sub-sites in Indian patients. [3] Here, 
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head and neck cancers are the second most common cancer in males 
and fourth most common cancer in females. [9] 
 
3. Aetiology: 
Though cancer pathogenesis is an interplay of various factors 
including molecular genetics, environmental and lifestyle, tobacco in 
any form, alcohol and Human Papilloma Virus (HPV) infection have 
been the established risk factors for development of head and neck 
squamous cell carcinoma.  
 
a. Tobacco: Tobacco-related cancers represent around 42% of male 
and 18% of female cancer deaths in India. [3] Tobacco may be 
consumed either in the form of smoking or in smoke-less form. 
 
Smoking: Tobacco smoking can be in the form beedi, hookah, 
cigarettes, reverse smoking and cigars has been found to be an 
independent risk factor in 85-90% of the patients. [10-12] Cigars are 
the most dangerous with tobacco content equivalent to that of two 
and a half cigarettes. Tobacco smoking in various studies has shown 
a strong association with aero-digestive tract tumours with risk 
escalation of about 5 to 25-fold among smokers compared to never 
smokers. [13] Ten years after quitting, the risk of a smoker is reduced 
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by 50%. [12] Head and neck cancer patients who receive radiation 
treatment and yet continue to smoke have a lesser likelihood of 
achieving a complete response. [14] 
 
Smokeless tobacco: Smokeless tobacco can be in the form of 
gutkha, khaini, zarda, mixed with pan and lime. Practice of chewing 
tobacco quid and placing it in the gingivo-buccal sulcus develops a 
chronic local irritation and over time leads to carcinogenetic 
changes. 
 
Paan Masala: Paan Masala with its various flavouring and additive 
compounds consisting of nitrosamines and phosphates was the most 
dangerous compounds. Various studies have shown that chewing 
pan masala can develop cancer within a very short lead time as 
compared to tobacco. Also its easy availability has caused a spike of 
head and neck cancer among very young age groups. Thus, the ban 
on sale of these products in 2013 was a welcome move by the 
government. 
 
Areca/ Betel Nut: WHO in a recent statement declared areca nut 
chewing as a potential of oral pre-malignant lesions and 
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carcinogenesis. Areca nut is commonly used in paan, mukhwaas (an 
Indian after meal mouth freshener). 
 
b. Alcohol: Alcohol by itself has shown to increase the risk of head 
and neck cancer by fivefold. [15] Along with tobacco it has a 
synergistic action in carcinogenesis. [16] A meta-analysis of 26 
studies that analysed effects of alcohol showed a relative risk of 
1.85-6.01 based on the quantity of alcohol consumed daily. [17] Oral 
cavity and pharynx are the sites most exposed during alcohol/ 
tobacco intake and hence these sites show an increased propensity to 
develop a primary tumour. 
 
c. HPV Infection: HPV infection with serotypes 16 and 18 have been 
associated with head and neck cancer, most commonly, 
oropharyngeal tumours. [18-20]These infections are mostly acquired 
due to increase in unnatural or risky sexual behaviour patterns. Risk 
factors include high lifetime vaginal or oral sex partners, sero-
positivity for HPV-16 viral capsid protein antibodies. HPV-16 is the 
most common serotype and positivity is observed in 60-90% of the 
oropharyngeal cases. A meta-analysis of all studies which assessed 
the relation between HPV infection and head and neck cancers 
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showed an improved Overall Survival (OS) and Diseases Free 
Survival (DFS) among oropharyngeal tumours that showed HPV 
infection positivity. [21] In the re-analysis of RTOG 0129 study, HPV 
status was independently associated with improved outcomes. HPV 
positive tumours have shown to have better prognosis regardless of 
the treatment modality utilised. 
 
d. Dietary Factors: Diet low in fibre, fresh fruits, vegetables and 
source of anti-oxidants, increased consumption of red meat and fatty 
diet have been associated with risk of aero digestive malignancies. 
 
4. Molecular Biology:  
Case-control studies have shown that first degree relatives of 
patients with head and neck squamous cell carcinoma have a 3.5 to 3.8 
fold risk of developing HNSCC themselves. [22] Thus this hints towards 
underlying genetic mechanisms leading to carcinogenesis. 
Carcinogenesis of head and neck tumours results from multiple genetic 
and epigenetic alterations of molecular pathways in the squamous 
epithelium. The following signalling pathways have been implicated in 
HNSCC. 
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A. P16/ p53/ Cyclin D: P16 is an inhibitor of cyclin-dependent kinase 
(CDK), which is required in G1 cell-cycle regulation. Loss of p16 
protein has been observed in most advanced premalignant lesions 
and appears necessary for immortalization of keratinocytes.[23] 
Inactivation of p53 is the most common genetic change in all of 
human cancer. [24] Role of p53 is to halt cell-cycle progression if 
there is DNA damage and induce apoptosis with inadequate DNA 
repair. Mutations of p53 result in a progression from pre-invasive to 
invasive lesions. The prevalence of p53 mutations is greater in 
patients who smoke and drink alcohol, thus establishing the causal 
role of these carcinogens. Further, constitutive activation of 
oncogene cyclin D1 has been shown to confer a growth advantage in 
HNSCC. [25] Other tumour suppressor genes, including Rb and p16, 
are negative regulators of the cyclin D1 pathway and often are 
inactivated in human neoplasms. Cyclin D1 amplification is 
independent of p16 inactivation in head and neck cancers. [26] 
 
B. PI3-K/ AKT/ mTOR: Mutation in the PI3-K pathway are seen in 
many human cancers and activation of PI3/ AKT/ mTOR pathway 
has been associated with carcinogenesis of the head and neck 
tumours. [27] PI3-K mutations bring about drug resistance, growth 
8 
 
advantage and transforming capacity. [28] PI3-K are activated by 
tyrosine kinase inhibitors including EGFR and oncogenic proteins 
that results in subsequent phosphorylation and subsequent activation 
of AKT. PI3-K also brings about activation of mammalian target of 
rapamycin (mTOR), which in turn activates a kinase that regulates 
protein synthesis. 
 
C. Epidermal Growth Factor Receptor (EGFR): EGFR is a receptor 
tyrosine kinase from the ErbB family of cell surface receptors. Once 
activated it can signal via the MAPK, Akt, ERK and Jak/ STAT 
pathways which are related to cellular proliferation, invasion, 
angiogenesis, metastasis and apoptosis. [29] Almost 80-90% of the 
HNSCC have dysfunction of EGFR receptor and its related 
pathways. [30] Elevated levels of EGFR expression confer a worse 
disease free and cause-specific survival. [31] Thus, strategies and 
molecules have been formed to target the EGFR pathway like 
tyrosine kinase inhibitors (TKIs) and monoclonal antibodies. 
Cetuximab is one of the vastly studied monoclonal antibody against 
EGFR which has shown to improve overall survival and duration of 
loco-regional control. [32] It has been approved by US-FDA for use 
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in HNSCC. Other agents like TKI Gefitinib and Erlotinib have not 
shown any survival advantage in the similar setting. [33] 
 
D. Human Papilloma Virus (HPV): HPV is a double stranded circular 
DNA virus with affinity for squamous epithelium. [34] Over 
expression of the E6 and E7 oncoproteins contained in the viral 
genome disrupt the function of tumour suppressor Rb and p53 genes 
which in turn results in carcinogenesis. [35] HPV positive tumours 
have shown to have poorly differentiated and basaloid histology 
frequently. It has also been shown that human epithelial cells 
expressing E6 and E7 genes from HPV-16 become immortal. [36] 
 
5. Clinical Presentation: 
Almost all the patients will present with a common symptom of 
nutritional insufficiency that is loss of appetite and loss of weight along 
with other long standing constitutional symptoms. The other symptoms 
at presentation are usually specific to the site of primary tumour. Oral 
cavity lesions present with an ulcero-proliferative or indurated lesion 
over the tongue/ lip/ buccal mucosa/ palate. The lesion might be 
associated with pain which might be aggravated by food intake. In 
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oropharynx and hypopharynx, the usual presenting symptom is 
dysphagia or majority might even present with cervical lymph 
adenopathy in absence of symptoms from the primary. The growth or 
cervical lymph nodes might cause secondary symptoms by mass or 
pressure effect on neighbouring structures in the form of pain, 
breathlessness or stridor. Laryngeal primaries are usually detected early 
in their course because of prominent symptom in the form of 
hoarseness of voice. Some cases of advanced primaries might present 
with bleeding or severe stridor accounting as pure oncologic 
emergencies.  
 
6. Prognostic and Predictive Factors: 
Various literature reviews and trial data have established the 
following prognostic factors in cancer of head and neck. 
 
A. Tumour Size: The T stage in TNM is one of the most important 
prognostic factor which can affect the prognosis. The local control 
rates and survival rates are seen to diminish with advancing T stage. 
Tumour thickness and depth of invasion increase the risk of regional 
metastases. [37] 
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B. Nodal Stage: Cervical lymph node metastases is one of the most 
significant predictor of outcome. [38] Patients with positive cervical 
lymphadenopathy have their 5 year survival rates reduced by 50%. 
[39] Multiple levels of lymph node positivity or Extra-capsular 
extension (ECE) worsen the prognosis further. [38] 
 
C. Tumour Site: Cancer of larynx has better prognosis compared to 
oral cavity, oro and hypopharynx. This can be attributed to pathways 
of tumour spread and lymphatic network of that particular site 
(Glottis has sparse lymphatics compared to other sites which have a 
dense lymphatic drainage). 
 
D. Miscellaneous Factors: Peri-neural invasion, lympho-vascular 
invasion, post-operative margin status have also shown prognostic 
implications in various studies. Histologic Grading has not been 
established as an independent prognostic factor due to wide 
variations in its pathologic interpretation. [37] 
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7. Treatment Synopsis:  
Ideal management for locally advanced head and neck cancer is a 
multi-modality approach incorporating all three disciplines of oncology 
namely surgery, radiation and chemotherapy. For early stage cancer, it 
can be either radiation or surgery, both giving equivocal local control 
rates at most of the sites. The choice largely depends on the primary 
physician and the patient’s preference. Locally advanced lesions are 
technically difficult to operate upon, hence, concurrent chemoradiation 
forms the definitive choice for such patients. Though the toxicity of 
such combined modality treatment is much higher compared to 
radiation or surgery alone, randomized controlled trials have shown that 
most of the toxicities are manageable and tolerable and that the 
combined treatment helps to achieve a higher cure rate compared to 
radiation alone. Failures after concurrent chemoradiation and those with 
residual disease can be taken up for salvage surgery. 
 
A. Principles of Surgery: All cases of head and neck cancer should be 
examined by an experienced head and neck cancer surgeon to assess 
the resectability. Surgery is the definitive modality where by the 
entire tumour can be removed en block along with a comprehensive 
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neck dissection. Neck dissection would be ipsilateral in well 
lateralized lesions. For lesions crossing the midline or primary sites 
having bilateral drainage, a bilateral neck dissection should be 
performed. In a node negative case showing deeper invasion of the 
primary, neck dissection is only elective and hence a selective 
dissection can be performed while preserving the major structures. 
In cases that the surgeon feels can be technically challenging or 
where complete resection is doubtful, may be taken up for 
concurrent chemo-radiation. The terms resectable and unresectable 
have been replaced by moderately advanced and very advanced as 
the tumour is never unresectable. It is either that the surgeon feels 
technically, the clearance would not be adequate or the patient is 
medically unfit for surgery. Surgery enables to examine the 
histopathology of the tumour upfront without any radiation induced 
alteration in tissue. It also enables to reserve radiation for any 
adverse pathological feature seen in the post-operative specimen. 
Reconstructed tissues and grafts heal up well prior to radiation than 
in an irradiated case as the local micro vascular changes do not 
occur. 
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B. Principles of Systemic Therapy: The landmark data from meta-
analysis of various trials of chemotherapy in head and neck cancer 
(MACH-NC)[40] has shown that concurrent chemotherapy gives an 
absolute benefit of 6% compared to radiation alone. Single agent 
Cisplatin (D1-D22-D43) is the standard regimen for all head and neck 
cancer cases planned for concurrent chemoradiation. No added 
advantage was seen with Cisplatin combination chemotherapy along 
with radiation. No other drug in single agent setting showed benefit 
similar to Cisplatin. Hence NCCN Guidelines recommend under 
category 1, only single agent Cisplatin as the standard regimen in 
concurrent setting. Further, induction chemotherapy has shown an 
overall survival benefit of about 2%. Induction with 2-3 cycles using 
three drug regimen of taxol, platinum and 5-flurouracil has shown 
superiority over two drug regimen in the form of PF. The benefit of 
induction is seen most in hypopharynx followed by oropharynx and 
least in larynx and oral cavity. However, in the paucity of data, 
NCCN favours the use of induction chemotherapy only as a category 
3 recommendation i.e. there is a major disagreement towards its use. 
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C. Principles of Radiation Therapy: Radiation in early stage HNSCC 
can be delivered either in the form of tele therapy or brachytherapy 
or combined with tele therapy followed by a brachytherapy boost. 
Advantages of radiation are that the functional and anatomic 
structure of the involved tissue is maintained and hence the 
morbidity of treatment is low. With incorporation of concurrent 
chemotherapy, many locally advanced cases can achieve a good 
local control along with organ preservation. Newer techniques like 
3D-Conformal and intensity modulated radiation therapy help in 
minimising the adjacent normal tissue doses and consequential 
toxicity while at the same time allow for dose escalation at the 
tumour which may transform into an improved local control. When 
chemoradiation is the definitive modality, all at-risk cervical lymph 
node stations are to be incorporated into low-risk, intermediate-risk 
or high-risk CTVs (Clinical Target Volume). The dose prescription 
will vary depending on the risk category from 44-66 Gy. When 
given post-operatively, the indications for Adjuvant radiotherapy are 
advanced T stage, multiple levels of lymph node positivity, peri-
neural and Lymphovascular invasion. Chemotherapy is added to 
post-operative radiation in cases of margin positivity and extra 
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capsular extension (ECE).Radiotherapy is generally given in 
fractions. The different types of fractionation are: 
 
Conventional: Dose fractions of 1.8-2.2 Gy are considered to be 
conventional. These are the usual recommended dose fractions 
under various guidelines of cancer treatment. For head and neck 
cancer, the total dose should be 66 – 70 Gy, in 2.2 to 2 Gy fractions 
respectively. 
 
Altered Fractionation: It can be of following types: 
i. Accelerated: Decreases the overall treatment time to counter 
the accelerated repopulation in tumour cells during the 
treatment. Improves loco regional control. 
 
ii. Pure accelerated: Decreases the overall treatment time 
without altering the total dose or fractionation. 
 
iii. Hybrid accelerated:  
1. Type A: Reduced total dose along with reduced overall 
treatment time. 
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2. Type B: Reduced treatment time, total dose unchanged 
and is given over two-split courses. 
3. Type C (accelerated concomitant boost): Total dose 
unchanged, overall treatment time reduced with 
concomitant boost delivered as a second daily dose, 
given at least 6 hours apart. 
 
iv. Hyper fractionated Radiotherapy: Total dose is increased 
while the dose per fraction is significantly reduced and the 
number of fractions are increased so as to deliver more than 5 
fractions a week. The overall treatment remains largely 
unchanged. 
 
Brachytherapy: No radiotherapy discussion in head and neck 
cancer is complete without addressing the principles of 
brachytherapy. The unique advantage of this mode of treatment is 
that high dose can be delivered directly into the target tumour 
tissue with minimal spillage of the dose into the surrounding 
normal tissue. Thus, in spite of proton therapies and other 
modern conformal techniques, brachytherapy is also regarded as 
18 
 
the highest degree of conformal therapy. Brachytherapy can be 
delivered using following techniques: 
 
a. Surface/ mould applicators: For lip and buccal mucosa 
lesions which are accessible externally. 
b. Interstitial implants: These are applied for lesions of tongue 
and soft palate which are infiltrative or diffuse. 
c. Intra-cavitary applicators: These can be used for optimal 
dose delivery for pharyngeal lesions where surface or 
interstitial implantation is not possible. 
The usual isotopes used for High Dose Rate (HDR) 
treatment are Ir192and Co60. The recommended fractionation is 3 
Gy for HDR application, to a total dose of 21 Gy for boost when 
used after tele-therapy of 45-50 Gy. When using it as a sole 
therapy in early stage lesions, fractions of 3-6 Gy to a total dose 
of 45-60 Gy are recommended. Brachytherapy can be a useful 
technique in cases of recurrent/ advanced disease where surgery 
or re-irradiation with substantial doses of external beam 
radiation are not feasible by providing good tumour control and 
symptom relief. 
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Precautions specific for brachytherapy treatment delivery: 
a. Space between adjacent interstitial implants should be at 
least 1 cm to provide homogenous distribution in the 
entire tumour 
b. Proximity to jaw or other bones should be more than 1 cm 
to reduce the risks of osteoradionecrosis. 
c. CT based delineation of treatment volume to plan the 
number of interstitial catheters required for homogenous 
dose coverage. 
d. Other surgical precautions such as normal bleeding/ 
clotting profile, anaesthetic fitness apply. 
 
Mandatory precautions prior to external beam radiation of 
head and neck: 
 
i. Dental evaluation and management: Xerostomia and 
salivary gland dysfunction are the major side effects after any 
head and neck irradiation. These side effects drastically 
increase the risk of dental sequelae such as caries, alveolar 
infection and eventually osteoradionecrosis (ORN). Radiation 
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also increases the risk of demineralisation by directly 
damaging the dental tissue. Radiation related caries and tissue 
changes may appear within first few months post treatment. 
[41, 42] Risk should be assessed for caries and periodontal 
disease. All potential sources of infection should be 
eliminated. Any dental extractions, should be performed at 
least 2 weeks prior to initiation of radiation therapy. Topical 
fluoride may be added for daily use if risk of caries is high. 
Regular rinsing of mouth with commercially available 
solutions or using home-made solutions of salt and soda 
bicarbonate in water. 
 
ii. Nutritional Management: Patients with head and neck 
cancer are prone to weight loss result of their disease process 
per se, health patterns and treatment related toxicity. 
Management of nutritional intake is as essential as the therapy 
itself because studies have shown its influence on outcome 
and complications. Prophylactic feeding procedure is not 
recommended in patients with a good performance status, no 
signs of significant pre-treatment weight loss, airway 
obstruction or severe dysphagia/ dehydration. 
21 
 
iii. Metallic implants/ accessories: Patients should be asked to 
remove all metallic accessories such as gold ornaments or ear/ 
nose rings. Those with metallic implants in the irradiated area 
should be planned for radiotherapy prior to surgery or should 
be monitored carefully for early toxicities, if radiation cannot 
be avoided. Photons from the radiation beam are prone to 
produce scatter electrons on interaction with metal surfaces. 
These secondary electrons, having a lower depth of 
penetration, remain confined to the skin and subcutaneous 
tissues thus giving rise to a dose augmentation and increased 
local toxicity. 
 
D. Principles of Palliation: Palliation is often described as “to cure 
sometimes, to treat often, comfort always”. The term “palliative” is 
conventionally used to describe strategies for patients in whom 
“cure” is a distant option because of disease or patient related 
factors. According to All India Institute of Medical Sciences data, 
70% of head and neck cancer present in advanced stages where cure 
is difficult to achieve. [43] Palliation can be delivered using a single 
modality of treatment which relieves the symptoms to the maximum 
and at the same time does not add to toxicity or morbidity. Hence, it 
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can be a debulking surgery to remove a huge fungating neck nodal 
mass to relieve pressure effects and discomforting smell. Or it can 
be radiation, usually short course and hypofractionated targeted to 
symptomatic primary/ nodal mass for relieving symptoms and at the 
same time avoiding patient discomfort that accompanies a protracted 
course. Chemotherapy also has a role in palliation of some solid 
tumours, less frequently in head and neck, and in cases where 
extent/ systemic spread or performance status rules out the use of 
other modalities. 
 
8. Very Advanced Lesions:  
 
Even with robust screening and patient awareness programs, the 
head and neck cancer cases present in our day to day practice more 
often in the advanced stage. The various psychosocial factors which 
lead to delay in diagnosis and seeking treatment include beliefs like 
‘cancer a curse’, ‘trivial ulcers in the mouth are benign’ and also the 
fear that ‘the prolonged treatment will affect the family’. [44] Sometimes 
delay occurs between diagnosis and initiation of treatment due to futile 
advice from relatives to try local remedies and avoid expensive and 
morbid cancer treatment. With advanced nature of lesions, the 
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performance status, age, willingness of patient to undergo aggressive 
toxic treatment and many other factors come into play. Young patients 
with good performance status and very advanced lesions can be taken 
up for concurrent chemoradiation and may be followed up with surgery 
for taking care of the residual disease. Induction chemotherapy may be 
tried but trials are yet to show any substantial improvement in survival 
benefit. Practically, even with advances in chemotherapeutic drugs, 
molecular targeted therapies and radiation techniques, the benefits in 
loco-regional disease control or survival have not increased as 
drastically as desired for these sub group of patients. Poor performance 
status of patients with very advanced disease, invariably tilts the 
treatment decisions in the favour of palliation. Patients with head and 
neck squamous cell carcinoma also have issues pertaining to nutrition. 
From early in the course of the disease, the growth obstructing the aero-
digestive tract or pain associated with the lesion compromises the 
swallowing ability. Thus with a chronic nutritional deficiency, these 
patients usually report with a compromised performance status. Socio-
economic issues have also been a major reason for delaying or 
defaulting protracted courses of radiation treatment among our patients. 
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9. Role of Radiation in Palliation:  
Due to the involvement of the upper aero-digestive tract, the 
patients often present with severe symptoms and there are no evidence 
based guidelines for standard practice of palliative care in advanced 
head and neck cancer. [45, 46] With advanced lesions and poor 
performance status, surgery is generally not feasible, considering 
sizeable amount of disease would still be left behind. Chemotherapy 
has shown little efficacy in palliation of bulky head and neck cancer 
lesions. Despite sufficient evidence on the benefits of palliative 
hypofractionated radiotherapy in patients with advanced solid tumours, 
there is scarcity of such data in advanced HNSCC. Poor patient 
compliance to treatment, limited enrolment cause difficulties in 
outcome assessment. Limitations with respect to personnel, radiation 
delivery equipment in developing countries makes timely delivery of 
palliation difficult. The role of radiotherapy in the palliation of 
advanced HNSCC is not clear. [47] A short course of high dose radiation 
can downsize the bulk of the tumour within short span of time, resulting 
in good symptom relief with minimal residual toxicity. However, there 
are still no appropriate tools or batteries to assess for symptom relief or 
effectiveness of palliative radiotherapy in HNSCC. 
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10. Study Rationale: 
The paucity of data regarding the optimal use of hypofractionated 
radiotherapy in head and neck cancer for a population where 60-70% 
cases usually present in very advanced stages, has been the idea behind 
this study protocol. Hypofractionation implies use of larger dose per 
fraction with lesser number of fractions so as to deliver the equivalent 
biological effective dose (BED) in a shorter duration of time. Figure 
1.10.1 indicates that for an increase in dose per fraction (df) over the 
reference value of 2 Gy, for an isoeffect, the total dose should be 
reduced as indicated by the curve. Due to a low 
α/β ratio, curves for late 
reactions are steeper than those for early reactions and for tumours, 
which have a high 
α/β ratio. Hence, if df is increased to 4 Gy per 
fraction and considering the
α/β ratio for late reacting tissues to be 3 Gy, 
then the total dose must be reduced to 0.75 of its reference value i.e. a 
25% reduction. For the tumour tissue, the 
α/β being 10 Gy, with df of 4 
Gy, the isoeffective total dose of the tumouricidal dose (70 Gy) would 
work out to be about 58 Gy. A reduction by 25% will thus under dose 
the tumour and compromise local control. Large dose per fractions are 
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radio-biologically unfair as the late reactions are enhanced considering 
the lower 
α/β ratio for these tissues. However, the radiobiological 
principles are not minded as the aim of this study is only palliation of 
symptoms and not local control, and also, as the expected survival is far 
lesser than the time required for onset of late symptoms. 
Hypofractionated schedules have the advantage of being more 
convenient for the patient, their care takers and also for health care 
providers by sparing essential resources. 
Figure 1: Isoeffect relationship 
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The LQ model (linear – quadratic) helps in calculating isoeffect 
relationships for radiotherapy based on common basic assumptions, 
thus it makes the computation of different dose fractionation schedules 
easy. The effectiveness of different schedules of different total doses 
and doses per fraction can be easily compared by converting each 
schedule into an equivalent dose of 2 Gy fractions which would give 
the same biological effect. The equation for the above use is given as: 
 
EQD2 =  D d + (
α/β) 
           2 + (
α/β) 
 
 
Here, EQD2 is the dose in 2 Gy fractions that is biologically 
effective to a total dose D delivered using the dose per fraction of d 
Gy. Since 2 Gy is a commonly used fractionation, it helps in 
communication among different radiation oncologist specialists and 
therapists regarding the efficacy of a given dose fractionation 
schedule. 
 
11. Concept of overall treatment time (OTT):  
Radio-biologically speaking, overall treatment time is one of the 
major factors which governs treatment response. Biological effects of 
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radiotherapy are known to be compromised with increase in the 
overall treatment time. Initial radical trials were formulated in split-
courses so as to reduce acute normal tissue toxicity. However, with 
the observation that even the tumour control is compromised, this 
practice has been given up. Accelerated repopulation is known to 
occur in head and neck cancer with a lag phase. Continuous Hyper-
fractionated Accelerated Radiotherapy (CHART) study in head and 
neck cancer has established that onset of accelerated repopulation 
begins at 22 days. [48]Various other studies have given the range to be 
around 21 – 30 days. 
 
12. Rationale for Split Course:  
The dose of 20 Gy given in 5 fractions of 4 Gy each, is a sizeable 
dose over a short period of 5 days with a BED value of 28 Gy10. To 
allow for normal tissue recovery from the acute toxicities of this dose, 
a gap of 2 weeks is allowed. It has been shown that mucosal 
regeneration time in head and neck is 3 – 4 days [49]. Also, the 
assessment at the end of two weeks helps to decide upon the patients 
that are suitable for a high dose treatment for achieving the goal of apt 
and prolonged symptom relief. Thus, after the recovery, one more 
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dose of 20 Gy is delivered similarly in 5 fractions. In a European 
study, a gap of 3 weeks was given for a total course BED value of 78 
Gy delivered in two split courses. For our study, the total radiation 
course BED value is calculated to be 56 Gy, delivering 28 Gy in each 
course. Delay until the onset of accelerated repopulation largely 
minimises the effect of the 2 week gap on tumour response in this 
particular treatment schedule which has an OTT of 28 days.  Thus, the 
treatment is planned to complete just beyond the accelerated 
repopulation is set in. The Equivalent dose in 2 Gy for this regimen is 
46.7 Gy using 
α/β of 10 Gy for acutely reacting tissue and tumour 
tissue. Thus, if the dose recovery per day as a result of tumour 
repopulation is considered to be 0.7, the dose recovered by the tumour 
tissue with the two week gap can be calculated to be 4.2 Gy. Though 
it is not warranted, in a palliative setting where symptom relief and 
not abolishment of all tumour clonogen is the primary goal, 
accelerated repopulation is less of a concern. 
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REVIEW OF LITERATURE 
 Use of radiation in medicine dates back to late 19th century after the 
discovery of radioactivity and effects of x-rays. Since then, the field of 
radiotherapy has grown by leaps and bounds from initial superficial and 
deep xray, orthovoltage units to megavoltage treatment using Co-60 unit or 
the modern day Linear Accelerators (LINAC). There has also been 
development in delivery techniques with the advent of conformality and 
intensity modulation of the treatment beams under computer guidance. The 
various external beam radiation (EBRT) technologies are described below: 
 
a. Co-60 EBRT Unit: 
 
The inception of Co-60 treatment units for clinical use was in 
early 1950s. The advantages of this unit are cost effectiveness, easy 
availability, short treatment times, low maintenance, and personnel-
efficiency. The major disadvantage of cobalt unit is the radio-active 
treatment source exposing the personnel to radiation risk. Usual 
treatment is 2 Dimensional where the minimum standard of care today is 
3 Dimensional therapy. Other disadvantages include regular change of 
source due to decay, prolonged treatment times towards the end of 
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source, frequent re-calibration for output assessment. Only photon beam 
therapy is possible, electrons and neutrons though produced secondarily, 
are not of any clinical significance. 
 
b. Linear Accelerator (LINAC): 
 
Linear accelerators came into use for oncologic therapy in the 
early 1970s. The major advantage of this unit is no radioactive source 
thus eliminating the issues of personnel exposure, source decay, output 
calibration and source change. A variety of beams and energies such as 
photons (4, 6, 15 MV) and electrons (6-18 MeV) can be produced and 
chosen for treatment as desired. Electron beams are of advantage for 
treating superficial tumours. Higher energy beams have the unique 
“skin-sparing” effect. It also allows for 3-D treatment, and use of 
intensity modulated RT after mounting multi-leaf collimators. The 
disadvantages of LINAC units are primarily high costs, in a resource 
strained country like ours followed by high demand of trained personnel, 
treatment time, patient load, high maintenance costs, and rigid quality 
assurance requirements. 
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c. 3D Conformal Therapy: 
With advances in physics, deeper concepts of three dimensional 
picture came into picture. It was understood that 2D fields were 
responsible for irradiating excessively large volumes of normal tissue 
which lead to toxicity and morbidity. Thus, with the help of Styrofoam 
blocks, fields conforming to the tumour tissue could be planned with 
minimal margin of surrounding normal tissue. However, preparation of 
Styrofoam blocks made the procedure tedious and lesser centres practice 
manual conformal technique now. 
 
d. Intensity Modulated Radiation Therapy: 
 
Further advances were with the development of multi-leaf 
collimators, which are basically lead blocks which can move in sync or 
separately so as to design an irregularly shaped field. Also, the dose to 
various parts of the tumour can be pre-planned with high doses in the 
bulk and lesser dose for the microscopic disease margin. The dose 
prescription then follows a complex logarithm so as to plan the MLC 
design, location and duration. This is known as “inverse planning”. This 
technique also helps in giving a boost dose to the gross tumour along 
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with the daily fraction which is known as “simultaneous integrated 
boost”. 
 
e. Image Guided Radiation Therapy: 
 
In the recent years, concern has been expressed over tumour 
motion during radiation delivery (intra-fraction) and between the 
consequent radiation fractions (inter-fraction). Techniques such as gated 
radiotherapy, on-table imaging, and 4D imaging have evolved to 
compensate for tumour motion. Gated radiotherapy with-holds the beam 
delivery when the tumour is detected to move out of the field of 
irradiation until it returns back. The tumour motion is detected by the 
closed system of metal clips placed in the tumour, infrared receivers 
placed over patient’s skin near the tumour and ceiling mounted infrared 
emitters. On-table imaging verifies the tumour location with the help of 
megavoltage x-rays, just before the delivery of every radiation fraction. 
4D imaging incorporates the 4th dimension of time while acquiring CT 
imaging for planning. The computer detects tumour motion during the 
scan and arranges the images according to different phases of respiration 
temporally. Thus, the entire range of tumour motion is acquired in a 4D 
scan which can be either be used for expanding the CTV plan 
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accordingly or for gated radiotherapy. Image guided radiotherapy can be 
practiced using a simple Co-60 unit as well with on board imaging 
facilities. 
 
f. Stereotactic Radiation: 
 
Use of computer guided treatment planning and delivery is of 
utmost benefit in Stereotactic Radiotherapy techniques (SRS/ SBRT) 
where the system delivery accuracy lies within millimetres, which is 
required considering these techniques are used to deliver large doses to 
small volumes that are placed more often in eloquent areas. Image 
guidance is of utmost importance for practicing Stereotactic radiation. 
Stereotactic radiation can be delivered as a single high dose of radiation 
or as a fractionated treatment. When given in high doses, immediate 
tumour kill is achieved thus, being regarded as stereotactic radiosurgery 
as it is likened to a surgical tumour removal. SRS/SRT can be practiced 
using a LINAC, Gammaknife or Cyberknife™ machines. 
 
g. Heavy Particle Radiation: 
 
In the recent years, there has been great interest regarding the use 
of heavy particle beams like protons, carbon ions and neutrons. These 
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particles characteristically exhibit Bragg peak effect i.e. rapid dose build 
up at a depth followed by a sharp fall off. [50]Thus, the heavy particles 
are of particular interest in HNSCC, where the tumours are often 
surrounded by at-risk dose-limiting structures namely the parotid gland, 
pharyngeal constrictors. [51, 52]Recent studies have shown excellent 
parotid sparing and feasibility of high dose delivery with use of intensity 
modulated photon beams. However, because of huge costs involved in 
maintenance, personnel training and treatment with these machines, 
worldwide, very few centres practice this technique. 
 
Patient Treatment Selection in Advanced Head and Neck 
Carcinomas: 
There have been no definitive guidelines, prognostic or selection 
factors that guide treatment protocol selection in these cases. Radical 
loco-regional therapy is recommended to harness the possibilities of a 
cure. There have been conflicts often in minds of decision makers to 
identify patients suited for palliation alone as against those taken for 
curative therapy. The treating physician should consider the following 
aspects in absence of any consensus guidelines for deciding patients 
suitable for palliative treatment: 
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a. Inoperability 
b. Poor performance status 
c. Co-morbidities 
d. Short life expectancy 
e. Advanced spread of the tumour where cure is unrealistic 
f. Metastatic disease 
g. Socio-economic factors 
h. Symptom relief with minimal therapy is possible 
 
Chemoradiation in Advanced Head and Neck Carcinomas: 
 Standard of care for advanced unresectable HNSCC in patients with a 
favourable performance status is chemoradiation. Several randomized 
controlled trial’s data have shown that chemoradiation improves local 
control and provides a survival benefit compared to radiation alone. The 
rationale for combining chemotherapy with radiation are: 
a. Radio-sensitisation: The chemotherapeutic drug gets selectively 
taken up and concentrated in the tumour tissue and making them 
sensitive towards radiation induced cell kill. Radio-sensitizers do not 
have any inherent cytotoxic action. 
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b. Spatial co-operation: Radiotherapy acts loco-regionally while 
chemotherapy acts systemically to control the micro metastases. 
Radiation and chemotherapy do not act in synergy. 
 
c. Cytokinetic co-operation: Administration of the chemotherapeutic 
drug organizes the cells in particular phase of cell cycle such that the 
effect of radiation delivered subsequently, is enhanced. 
 
d. Hypoxia prevention: Cytotoxic drugs like paclitaxel improve tumour 
perfusion and oxygenation by direct action on tumour cells and 
reducing the tumour bulk. 
 
e. Normal tissue protection: Drugs like amifostine show selective 
uptake into the normal tissues and prevent platinum-DNA adducts 
along with free radical scavenging, thus reducing normal tissue 
toxicity. 
 
f. Prevent tumour repopulation: Accelerated tumour repopulation is 
known to set in after a potent cytotoxic stimulus. For HNSCC, tumour 
repopulation has been shown to set in as early as 10-14 days after 
initiation of the radiotherapy. Thus, along with radiation, cytotoxic 
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chemotherapy provides a supra additive effect to counteract the 
tumour re-population. 
 
Chemotherapy in relation to radiation can be delivered in the 
following sequences/ techniques: 
 
1. Sequential Chemoradiation: 
The early trials combining chemotherapy and radiation utilized 
the technique of sequencing chemotherapy first followed by definitive 
radiation, so as to control for the toxicities. The Department of 
Veterans Affairs Laryngeal Cancer Study Group compared ‘sequential 
therapy using three cycles of Cisplatin and 5-Flurouracil’ with ‘total 
laryngectomy followed by radiation’ for stage 3 or 4 laryngeal 
cancers. They observed that larynx was preserved in 64% cases at the 
end of 2 years. It was concluded that sequential chemotherapy 
increased the effectiveness of definitive radiation. However, the study 
was not designed to compare sequential chemoradiation with radiation 
alone. An update to the trial results later showed that complete 
response rates were 42% at the end of cytotoxic treatment. Thus, it 
proved that organ preservation was a possibility without affecting the 
survival of these patients.[53] 
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2. Concurrent Chemoradiation: 
With advances in science and greater understanding of the 
tumour biology and of responses to chemoradiation, agents like 
Cisplatin and its combinations have been tried in various trials. The 
exact benefit and advantage of chemotherapy along with radiation was 
a grey area until Pignon et al came up with the updated data on meta-
analysis of chemotherapy in head and neck cancers (MACH-NC). 
[40]The data showed an absolute benefit of chemotherapy to be 6.5% at 
five years. No significant difference on survival was observed with 
addition of chemotherapy. Multi-agent chemotherapy did not show 
any benefit in the concurrent setting compared to single agent 
regimens. Among the various drugs tried as single agent viz. Taxols, 
5-Fu, Capecitabine, none showed superiority to Cisplatin. Only one 
trial which used cumulative doses of 140 mg/m2 of Cisplatin showed 
negative results, thus indicating that total dose of Cisplatin to achieve 
the proven benefit is important.  
 
3. Induction Chemotherapy: 
Recently, Pointreau Y et al in a randomized trial of laryngeal 
and hypopharyngeal SCC showed that overall response rate and 3-
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year actuarial larynx preservation rate was higher with TPF 
(Docetaxel with Cisplatin and 5-FU) compared to PF alone, however, 
at the cost of increased acute toxicity. [54, 55, 56]The two landmark trials, 
DeCIDE[57] and PARADIGM[58]have compared the effectiveness of 
‘induction chemotherapy followed by concurrent chemoradiation’ 
with ‘concurrent chemoradiation alone’. DeCIDE trial was to 
determine the survival benefit of treating with induction 
chemotherapy prior to concurrent chemoradiation. The induction 
chemotherapy regimen used was (TPF) Docetaxel, Cisplatin, 5-
Flurouracil while during the concurrent phase, combination of 
Docetaxel, 5-FU, Hydroxyurea was used along with hyper 
fractionated radiotherapy. Though the results showed a reduction in 
distal failure, it failed to show any improvement in OS. The 
PARADIGM trial as well did not show any significant survival 
advantage with incorporation of the induction chemotherapy to 
concurrent chemoradiation. 
Thus, all the available literature supports the use of single agent 
Cisplatin concurrently with radiation. RTOG-0129 and Intergroup 
studies have demonstrated the minimum threshold cumulative dose of 
Cisplatin to be 200mg/m2 for obtaining benefit. 
41 
 
Palliative Chemotherapy in Unresectable Head and Neck 
Carcinomas: 
Surgery is the recommended option for HNSCC, however, when 
the disease is unresectable the options are concurrent chemo 
radiotherapy if PS is good or else palliative treatment in the form of 
single agent radiotherapy or chemotherapy. Chemotherapy alone has 
less of a role in HNSCC and its mainstay is in the setting of metastatic 
disease/ recurrence that is unresectable or previously irradiated. Single 
agents and combination therapies have been tried in the scenario of 
recurrent/ metastatic disease. Despite all available chemotherapy 
regimens, median overall survival has remained less than 1 year in 
these patients.  
 
 There was an early study designed to find the advantage of 
combination of Cisplatin and 5-Fluorouracil versus their use as single 
agents. An improvement in overall response rate was observed with 
the combination regimen compared to use of either Cisplatin or 5-
Fluorouracil alone, though at the expense of increased toxicity. 
Patients with better PS and poorly differentiated tumours had a trend 
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towards better survival, however, they did not observe any significant 
difference among the two arms with respect to median survival. [59]  
 
 Later, with introduction of newer taxanes, EORTC investigated 
the role of single agent Docetaxel for advanced HNSCC. They 
observed a response rate of 32% (95% CI 17-47%) but along with a 
61% incidence of short-lasting grade 3-4 neutropenia. They however 
concluded that, Docetaxel is an active drug and that the toxicities 
were manageable with supportive therapy. [60] 
 
 With notable activity of vinca alkaloids in various solid tumours, 
efficacy of Vinorelbine was evaluated in a phase II study of recurrent 
or metastatic lesions. Overall response rates of 14% were observed, 
with median duration of response being 19 weeks. Grade 3-4 
toxicities were observed in 53% of the patients while treatment related 
deaths were reported in two patients.[61] 
 
 Further, an inter group trial of ECOG was undertaken for 
comparing the combination regimens viz. Cisplatin/ 5-FU and 
Cisplatin/Paclitaxel. No significant differences in survival or response 
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rates were observed.  Toxicity profile of both the treatments arm were 
also similar. Thus, this trial was negative and both the arms were 
equally effective in matched individuals. [62] 
 
 In beginning of the 21st century, Cetuximab, a monoclonal 
antibody against epidermal growth factor receptor (EGFR) was 
developed. Thus, Herbst RS, et al studied the efficacy of combining 
cetuximab with cisplatin with “EXTREME” trial. All patients were 
initially randomized to receive 2 cycles of either Cisplatin/ Paclitaxel 
or Cisplatin/ 5-FU. Those with stable or progressive disease were 
switched to combination of Cetuximab (weekly 250 mg/ m2after 
loading dose of 400 mg/ m2) along with Cisplatin (100mg/m2 
q21days). Objective response rates were observed in 44% of cases. 
Median duration of response and median overall survival were higher 
for patients that showed initial stable disease (7.4 months and 11.7 
months respectively) vs progressive disease (4.2 months and 6.1 
months respectively). Authors concluded that Cetuximab and 
Cisplatin combination is active and Cetuximab did not exaggerate the 
toxicity of the latter. [63] 
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 ECOG study group, formulated a phase III trial to assess if the 
addition of Cetuximab to Cisplatin improved the progression free 
survival (PFS). All patients were planned to receive Cisplatin every 4 
weeks along with either weekly Cetuximab (Arm A) or placebo (Arm 
B). Median PFS in trial arm was 4.2 months vs 2.7 months in the 
placebo arm. Median OS was 9.2 months (Arm A) vs 8 months. 
Objective response rates were 26% (Arm A) vs 10%. Thus, the 
conclusion drawn was that, addition of Cetuximab significantly 
improves response rate however, PFS and OS were not significantly 
improved. [64] 
 
The Southwest Oncology Group (SWOG) evaluated the 
combination of Docetaxel/ Carboplatin in advanced HNSCC. 
Response probability was 25% with 95% CI: 15-38%. Median PFS 
and OS were 3.8 months and 7.4 months. Considering that 61% of the 
patients experienced grade 3 or worse neutropenia, it was suggested 
that the regimen is active for patients with good performance status. 
[65] 
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The largest evidence towards combination of cetuximab with 
PF comes from the study by Vermorken JB et al, where they 
randomized a total of 442 patients into PF alone or PF + cetuximab. 
The study documented a significant prolongation of median overall 
survival from 7.4 months to 10.1 months in the combined therapy 
arm. It also significantly prolonged the median PFS time from 3.3 to 
5.6 months and the response rates increased from 20 to 36% 
(p<0.001). Incidence of grade 3 toxicity was low and overall toxicity 
profile appeared favourable. Thus, this trial provided the necessary 
evidence base for NCCN to make this combination, a category 1 
recommendation for first-line treatment of recurrent/ metastatic 
HNSCC. [66] 
 
After the success of cetuximab, smaller tyrosine kinase 
inhibitors such as Gefitinib were tried by Stewart JS, et al. They 
compared the survival of patients treated with 2 doses of Gefitinib 
with the then standard of methotrexate. This trial was negative as 
neither 250 mg nor 500 mg of Gefitinib per day improved survival 
when compared to methotrexate. The three arms were similar with 
46 
 
respect to median overall survival, objective response rates or QoL 
improvement rates.[67] 
 
Other regimens used were weekly Paclitaxel and monotherapy 
with Capecitabine. Weekly Paclitaxel was found to be as active as any 
other single agents. The toxicity profile was acceptable. [68] Use of 
Capecitabine also showed similar results. [69] 
 
Thus, to summarise, with all the available data from various 
clinical trials, there is enough evidence on hand to prove that various 
drugs used in monotherapy provide a 10-25% tumour response with a 
median survival of 6-8months. Combination therapies may increase 
the response rates up to 45-50% but without improving the survival. 
Only the triplet of PF plus Cetuximab has shown a survival advantage 
of up to 10.4 months and is now the standard of care. [70] Recently, the 
phase II trial GORTEC 2008-03 on an interim analysis suggested that 
Docetaxel, cisplatin along with cetuximab is effective with a 
manageable toxicity profile and might substitute the present standard 
of care.[71] 
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Palliative Radiation in Advanced Head and Neck Carcinomas: 
 Palliative radiotherapy aims at improving the quality of life with 
control of symptoms, it may or may not produce prolongation of 
survival. Existing literature is not substantial at present, to formulate 
guidelines regarding optimal palliative regimen with respect to time, 
dose and fractionation. The available evidence comes from various 
retrospective or case-control studies, single arm prospective trials and 
few small randomised controlled trials which have shown an 
improvement in outcome. [46, 47] 
 
Institutional policies vary in practices of palliative radiation with 
respect to fractionation, from conventionally fractionated radical 
doses of 60-70 Gy to short courses of hypofractionated radiotherapy. 
The idea of Hypofractionation is to strike a balance between quick 
and effective symptom relief against treatment toxicity. However, it is 
of concern whether protracted courses of radiotherapy with doses 
equivalent to curative schedules and their resultant increased toxicity 
actually improve outcome. 
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 A large study on natural history of untreated advanced HNSCC 
followed 808 patients from 1953-1990, until death and offered best 
supportive care in view of advanced tumour stage or poor 
performance status. Median overall survival was observed to be 3.82 
months (range: 1 day to 53.8 months). PS was the only significant 
predictor of outcome and survival. Those with better PS, favourable 
tumour location and extent were seen to survive for 4 or more years. 
The inference drawn was that palliative radiation neither improved 
survival or QoL of these patients. [72] 
 
 Similarly, Carvalho et al [73] analysed data from patients of 
advanced HNSCC, who were treated and those who were not treated 
until demise. Though their initial report was negative, later significant 
differences were observed with respect to survival in the two arms. 
The type of treatment or the tumour response to therapy did not 
influence the survival. 
 
Literature speaks of only a single randomised controlled, 
prospective trial testing the efficacy of short course hypofractionated 
radiotherapy of very advanced unresectable HNSCC dates back to late 
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20th century conducted by Weissberg JB, et al. A small population of 
64 patients was randomised to receive 60-70 Gy in conventional 
fractionation (2 Gy/ fraction in 30-35 fractions over 6-7 weeks) or 
short-course hypofractionated radiotherapy of 40-48 Gy (4 
Gy/fraction in 10-12 fractions over 2-3 weeks). The two arms were 
comparable with respect to tumour response, toxicity, symptom relief 
and overall survival. [47] 
 
 Another study conducted by Burns, et al. studied the records of 
76 patients treated with radiation of either curative or palliative intent. 
Patients treated with curative intent had mean OS of 19.4 months 
compared to 8.4 months in palliative arm. 2 year DFS was observed to 
be 29% in curative arm. Advanced stage in itself was a poor 
prognostic factor with mean survival of patients observed to drop 
down to 7.5 months with T4 tumour. Palliation of symptoms was 
deemed to be reasonable in 25% patients. However, they concluded 
that palliative radiotherapy was no better than best supportive care 
and that there was little benefit associated with treatment. [74] 
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 A retrospective analysis of 40 patients with advanced disease 
who were treated with either 30 Gy/ 10 fractions/ 2 weeks or 20 Gy/ 2 
fractions weekly, showed a good 1 year response rate of 65% and 
48% respectively and symptom relief rate of 57% and 38% 
respectively. The absolute survival as well as the cause-specific 
survival rates were 25% at 1 year. Successful palliation was achieved 
in greater than 50% of the patients treated with palliative intent. [75] 
 
 A series of 331 senior adults (> 70 years) was studied by 
Lusinchi, et al. Out of the total, 54 patients received 30 Gy in 15 
fractions over 3 weeks with palliative intent. Those with appreciable 
response (50%) were treated further radiotherapy to curative doses. 
The results published show that 33% patients could not complete the 
initial planned radiation dose of 30Gy due to low tolerance to 
radiation, poor PS or progression. Overall, the immediate and long-
term toxicities of radiation were favourable. Local control rate was 
19% at 3 years. OS at end of 2 and 5-years were 16% and 5% 
respectively. Due to retrospective nature of the study, symptom relief 
and QoL benefits could not be assessed. [76] 
51 
 
 Similarly, out of the 54 patients in a series of 160 patients treated 
with palliative radiotherapy, failure to complete planned course of 
radiation was seen in 33% due to disease progression or poor PS. At 
the end of two years follow up, two survivors were noted.[77] 
 
 With deeper understanding of radiobiological principles, a 
protocol was formed for cyclical accelerated split-course 
radiotherapy. Treatment delivered was 23.4 Gy/ 9 days, divided in 13 
fractions of 1.8 Gy, twice daily from days 3 to 11, and this was 
repeated for 3 cycles on day 22 and day 44, to deliver total tumour 
dose of 70.2 Gy/ 51 days. The overall toxicities of the treatment were 
found to be acceptable. Excellent symptom palliation was achieved 
when compared to historical controls treated with palliative 
radiotherapy. With the mean follow up period of 21 months, out of the 
32 patients treated, 28 achieved a complete response. Two year local 
control rate was 81% while the actuarial one and two year survival 
rates were 88% and 58% respectively.[78] 
 
 A phase I/II study[79] was performed using 3.7 Gy per fraction, 
twice daily over 2 consecutive days for a total of 14.8 Gy in 4 
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fractions. The schedule was repeated every 3-4 weeks to deliver a 
total dose of 44.4 Gy over 9-10 weeks. Of all the 37 treated patients, 
84.6% achieved reasonable palliation with minimal acute toxicity. No 
patients were observed to have any long-term complications from the 
treatment. The mean survival was reported as 4.5 months. Complete 
response was achieved in 11 patients while about 50% of them had a 
partial response. 
 
 A study conducted by Minatel et al, investigated the role of a 
higher dose palliative regimen with concurrent low dose Bleomycin in 
unresectable HNSCC. Fifty eight patients were treated in a split 
course fashion to a total dose of 50 Gy delivered in 20 fractions. First 
25 Gy were delivered along with concurrent Bleomycin (60 mg/ 6 
cycles) followed by a 2 week gap before the second course of further 
25 Gy. Authors reported a local control rate of 69%. Response was 
observed for a median of 7 months. Appropriate palliation was 
achieved in 81%. However, they also reported a grade 3 toxicity in 
46.5% of the treated cases which was manageable.[80] 
 
53 
 
 A recent retrospective study conducted by Stevens CM et al, 
examined the outcomes and prognostic factors for patients treated 
with radiation of palliative intent. Median radiation dose delivered in 
the analysable patients was 50 Gy (range 2-70 Gy) in a median 
fraction of 20 and median total treatment time being 29 days. Median 
survival time was found to be 5.2 months. They found on a 
multivariate analysis that, for patients considered unsuitable for 
curative radiation regimens, radiation dose was an independent 
predictor of overall survival as well as the treatment response. [81] 
 
 In “Hypo Trial” [82] conducted in Queensland by Porceddu SV  
et al, patients received 30 Gy in 5 fractions, 2 fractions per week 
which were atleast 3 days apart. In suitable patients, this was followed 
by an additional boost dose of 6 Gy for small volume lesion. Of the 
patients treated, 88% received the additional boost dose. Overall 
objective response was seen in 80%. An overall improvement in QoL 
was seen in 62% while 67% had improvement in pain scores. Median 
progression free and overall survival were 3.9 months and 6.1 months 
respectively. They concluded that the regimen provided effective 
palliation with excellent compliance and good symptom control. 
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 The experience of Rotterdam Cancer Institute with the “Christie 
Scheme” was published in Acta Oncologica recently. Patients 
unsuitable for curative treatment were treated with hypofractionated 
radiotherapy of 16 fractions of 3.125 Gy each. An overall response 
rate of 73% was noted while 21% had progression during or 
immediately after completing the scheduled course of radiation. At 
one year, the actuarial DFS and OS were 32% and 40% respectively 
which declined to 14% and 17% by the end of 3 years. Median 
survival was reported as 17 months with this schedule. Grade 3 or 
greater skin and mucosal toxicity was observed in 45% and 65% 
patients respectively. Pain and performance status improvement was 
seen in 77% and 47% respectively. It was concluded that Christie 
scheme provided excellent palliation and symptom control with 
acceptable toxicity.[83] 
 
 At PGI Chandigarh, 25 patients of unresectable head and neck 
cancer were treated with short course palliative radiation consisting of 
30 Gy delivered in 10 fractions over 2 weeks. An eleven-point 
numerical scale was used to assess baseline symptoms such as pain, 
dysphagia, cough, insomnia and dyspnoea. Symptom relief of greater 
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than 50% was observed at one month post-treatment among all 
patients with pain and over 90% of patients with dysphagia, insomnia 
and dyspnoea. Response was seen for a median duration of 3 months. 
None were reported to have grade 3 or greater toxicity.[84] 
 
 An All India Institute of Medical Sciences (AIIMS) study 
treated 505 patients with a short course radiation of 20 Gy, given in 5 
fractions of 4 Gy each over a week. Two or more symptoms were 
present in 71% of the patients. At the first month follow up, 37% were 
seen to achieve a partial response to the treatment and also maintained 
a good performance status that made them amenable for further 
radiation to attempt cure. A symptom relief of more than 50% was 
deemed good and such a relief was noted in 57% patients with pain 
and hoarseness, 53% for dysphagia, 59% for cough and 76% for 
respiratory distress. Maximum reported toxicity was grade 1 to 2 
mucositis and dermatitis. Median survival in treated patients was 
noted to be a little over 6 months. Those who received further 
radiation of curative attempt, had an improved overall survival of over 
a year. Overall, 37% patients achieved a partial response. [43] 
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 Further, the more popular regimen, the QUAD-SHOT, 
[85]consisted of 14 Gy in 4 fractions, twice daily at least 6 hours apart 
for 2 consecutive days and the entire cycle repeated at 4 weekly 
intervals for a total of three courses if no interim tumour progression 
was noted. The study was designed such that each cycle of radiation 
delivered the dose that was sub-optimal to that required for producing 
mucositis. At the same time, the maximum cumulative radiation dose 
was fixed considering the late effects of radiation. All patients had at 
least one cycle of radiation while 53% could complete all 3 cycles. 
Median OS was observed to be 5.7 months while the median PFS was 
3.1 months. None had grade 3 or worse toxicity and the tolerance was 
good with 44% reporting an improved overall QoL. This trial had a 
unique feature of patient rated judgement regarding the treatment 
worthiness. At the end of first, second and third cycle, 43%, 58% and 
63% of patients respectively, found the treatment worthwhile. 
 
 Theoretically, a higher total dose is required for maintaining 
reasonable palliation and controlling the tumour growth. Though 
various studies describe various schedules and fractionation schemes, 
overall, the literature supports the use of short-course, split-course or 
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the cyclical regimens compared to single large fraction treatment for 
palliation of very advanced head and neck cancer. 
 
Split-course Hypofractionated Radiation: 
 Split-course hypofractionated regimen is an attractive option for 
palliation of advanced unresectable head and neck cancer cases 
considering the following advantages: 
a. Effective regimen in various studies in literature 
b. Good symptom palliation 
c. Allows for normal tissue recovery in the two week gap and 
minimising toxicity 
d. Works with minimal load on resources or personnel 
e. Short course treatment making it acceptable for the patient, 
weighing the socio-economic factors 
f. Small hospital stay minimising health care costs 
Kancherla KN et al, [86]reviewed their institutional protocol at 
St.James Institute of Oncology, Leeds for palliation of advanced, 
unresectable head and neck cancer cases. Patient selection was done 
after discussion in a multi-disciplinary tumour board. Stage grouping 
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alone was not adequate and other factors including tumour extent, 
performance status, co-morbidities and socio-economic factors were 
taken into consideration before offering the option of palliative 
radiation. Patients who had received prior palliative chemotherapy 
were excluded. The protocol consisted of an initial course of 20 Gy in 
five fractions of 4 Gy each over one week followed by a two week 
gap. Patients were assessed for toxicity and responses at the end of the 
two week gap and those deemed fit were treated with a second course 
of similar 20 Gy radiation over a week. Radiation was delivered with 
parallel opposed fields, encompassing the gross tumour volume 
(primary tumour and nodal disease) along with a 1 to 2 cm margin, 
where required. Uninvolved nodes were not encompassed 
prophylactically. Maximum effort was taken to spare the uninvolved 
normal tissues. Where bulky disease infiltrated the skin, treatment was 
carried out with a surface bolus. Spinal cord tolerance was respected 
and fields modified after the dose of 37.5 Gy for late effects was 
received by the cord. Patients were assessed during the treatment and 
4-6 weeks after its completion. During the assessment at the end of 2 
week gap, those with major toxicities or disease progression were 
offered best supportive care. Symptomatic and tumour responses were 
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recorded on every assessment. Total of 44 patients were treated under 
this study out of which 11 received only the first course of 20 Gy. 
Further treatment was deferred in these patients due to treatment 
induced toxicity, disease progression or socio-economic factors. 
Symptoms at presentation were dysphagia (76%), pain (70%), 
breathlessness (24%) and hoarseness (24%). Two or more symptoms 
at presentation were seen in 73% cases. Reasons for taking these 
patients under palliative treatment were co-morbidities (54%), 
advanced age (39%) and poor PS at presentation (36%). Toxicity 
profile of the treatment was acceptable with only 18% experiencing 
some form of grade 3 toxicity. A major symptom improvement was 
noted in 52% of the cases, while 15% had no change and 6% had 
deterioration of symptoms. At the first follow up, 39% were shown to 
achieve a complete response while 33% had a partial response to the 
two courses of high dose radiation. Degree of response achieved 
correlated well with the symptom relief achieved. Median overall 
survival of the study population was noted to be 9 months (range: 3 - 
43 months). At the last follow up, 24% patients were alive while 70% 
had expired as a result of disease progression, recurrence or 
metastasis. At 1 and 2 years, progression free survival rates were 
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observed to be 42 and 35% respectively. On further analysis, higher T 
stage was associated with poorer survival. Complete response to 
radiation was associated with significantly higher PFS and OS. 
However, with the aim of this study being palliation and symptom 
relief, the focus is less on a formal tumour response. The authors 
concluded saying that split-course hypofractionated radiotherapy was 
a feasible option for palliation and it offered a good symptom relief. 
 
Thus, with this study, we are investigating the activity and 
feasibility of split-course hypofractionated radiotherapy among our 
population which largely consists of advanced, unresectable head and 
neck squamous cell carcinoma. 
 
 
  
 
 
 
 
 
 
AIMS AND 
OBJECTIVES 
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AIMS AND OBJECTIVES 
Primary Objective: 
To assess the symptom relief after a split course of palliative 
hypofractionated radiotherapy in patients with advanced head and neck 
squamous cell carcinoma. 
 
Secondary Objectives: 
a. To assess the Quality of Life (QoL) of these patients 
b. To assess the treatment related toxicity 
c. To assess the immediate loco-regional response  
 
 
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
The study design was a single arm, prospective study determining the 
activity of split course hypofractionated radiotherapy for palliation of 
advanced head and neck squamous cell carcinoma. 
 
The study protocol was formed and submitted to Institutional Ethics 
Committee. The patients were accrued into the study only after obtaining the 
necessary approval. Signed informed consent was obtained from all the 
patients who fitted the inclusion criteria and were willing for treatment under 
the prescribed study protocol. The study period was from January to August 
2014. 
 
1. INCLUSION CRITERIA: 
• Biopsy proven squamous cell carcinoma of the head & neck (SCCHN) 
• Primary tumour sites: oral cavity, oropharynx, hypopharynx, larynx 
• Stage 3 or 4 disease without evidence of distant metastases 
• No previous surgery/ chemotherapy or radiotherapy 
• ECOG performance status >2 
• Age < 70 years 
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• Medically manageable co-morbidities 
• Signed informed consent prior to initiation of protocol specific 
procedures 
 
2. EXCLUSION CRITERIA: 
• Previously received treatment for any other malignancy 
• Tumours of nasal cavity, paranasal sinuses, nasopharynx and salivary 
glands 
• Non squamous histopathology 
• Uncontrolled co-morbidities 
 
3. PRE-TREATMENT WORK UP: 
a. History and clinical examination: To note down the time to onset of 
         illness and symptoms, see the extent  
         of the tumour and regional nodes for  
         accurate clinical staging. 
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b. Symptoms at presentation:  Patient might be having one to many  
     symptoms at the time of presentation,  
        recording the severity of each 
symptom. 
 
c. Biopsy from tumour: Squamous cell carcinoma constitute 90% of the 
       head and neck cancer. Other uncommon   
       histology can be adenocarcinoma, adeno-   
       squamous, mucoepidermoid, lymphoepithelioma, 
       lymphoma, etc. For this study, only squamous cell 
       carcinoma is the inclusion criteria. 
 
d. Performance status: Many studies have shown a correlation between  
    performance status and survival outcomes in cases 
    of advanced head and neck cancer given palliative 
    treatment. 
 
e. Height and weight: To calculate the body surface area for drug dose 
   calculations. 
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f. Blood investigations: Complete blood count, renal and liver function  
       tests before initiation of each radiation course. 
 
g. CT scan Neck:  From base of skull to Root of Neck– Plain and  
Contrast before start of treatment and 4-6 weeks 
after completion.  
 
h. Chest X ray – PA view:  With advanced nodal disease, risk of lung 
    metastasis increases in head and neck cancer.
    Pharyngeal sub-sites with nodal disease of N2
    or greater have about a 15% risk of lung 
    secondaries. 
 
i. Dental evaluation and prophylaxis: To minimise the risks of dental  
            sequelae namely, caries, infections
            and osteoradionecrosis. 
 
j. Diet plan: Specific high protein diet plans were formulated for patients 
         undergoing high dose radiotherapy with the help of   
         institutional dietician. 
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k. Feeding procedure as warranted: Those presenting with severe pre- 
        treatment weight loss, dysphagia 
        or airway obstruction. 
 
l. Counselling to quit tobacco use: Every patient counselled personally for
      helping them to quit tobacco and  
 related  products. Continued smoking 
during treatment has shown poor 
outcomes. 
 
TREATMENT PLANNING: 
All patients were treated with parallel, opposed, lateral paired 
fields encompassing the gross disease and the draining lymph nodes. 
The treatment fields were open, non-wedged and without any beam 
attenuators, with dose prescribed to the midline depth of the two fields. 
Surface bolus was used were tumour or the nodal disease invaded the 
skin in the form of ulceration, fungation or necrosis. 
RADIOTHERAPY SCHEDULE: 
All patients after the initial staging and general work up and 
assessment were planned for radiotherapy. Radiotherapy was scheduled 
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in two courses, split by a two weeks gap for allowing normal tissue 
recovery. 
 
Each radiotherapy course consisted of 20 Gy delivered in 5 
fractions of 4 Gy each, one fraction daily. Radiation was delivered in a 
2-D setup using Co-60 tele-therapy unit, in parallel opposed fields. 
Gross tumour and the nodal disease were encompassed in the fields. 
Prophylactic irradiation of uninvolved nodes was not carried out. Spinal 
cord tolerance was well respected with the posterior border of the field 
shifted anteriorly to avoid spinal irradiation beyond the EQD2 of 40 Gy. 
Tight margins were given around the gross disease in an effort to 
minimise the toxicity to uninvolved normal tissues.  
 
Effort was made to start the radiation on first day of the week so 
as to complete the fractions by the fifth day of the week. Patients were 
then given a two week gap from the fifth fraction to attenuate the 
normal tissue toxicity. Treatment was delivered using surface bolus in 
cases with skin infiltration or nodal ulceration. They were then re-
assessed at the end of the two week period for symptom relief and 
toxicities out of the first course of treatment. Those with less than or 
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equal to grade 2 toxicities were further treated with another course of 
20 Gy radiation in further 5 fractions. Those with greater than grade 2 
toxicity were offered Best Supportive Care (BSC). Patients in whom 
the second course of radiation was delayed beyond the two week gap 
period due to worsening of performance status, were considered to have 
received only one course under the protocol. 
 
The Biological Equivalent Dose (BED) of the entire course of 
therapy was 56 Gy10 with an Equivalent Dose in 2 Gy (EQD2) of 46.7 
Gy for the tumour and for late reacting tissues, BED was 93.3 Gy3 with 
EQD2 of 56 Gy, unminding the two week gap. 
 
PATIENT CARE DURING TREATMENT: 
a. Watchful assessment of toxicities; suspension of radiation when 
treatment toxicity exceeded grade 2. 
b. Oral hygiene- mouthwash, regular oral rinsing, anti-fungal and 
antibiotics when clinically indicated. 
c. Dietary management and nutritional care 
d. Other basic symptomatic management with respect to cough, 
dyspnoea, insomnia etc. 
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ASSESSMENT: 
Following assessments were done on pre-defined time intervals 
for all patients that were treated under this study protocol.  
 
a) Symptoms: Symptoms were assessed before initiation of treatment, 
at the end of first course of radiotherapy, at the beginning and end of 
second course of radiotherapy and at the first month follow up. 
Symptoms were assessed and gauged using the symptom relief 
assessment scale at the end of treatment to assess the activity of the 
given treatment. The symptoms were recorded on a scale of 0 to 4 
during each assessment. The change in symptom scores were 
calculated by the differences between the readings at different time 
points. An improvement in symptom was thus denoted by a negative 
score (-) at the time of evaluation, while worsening of symptom was 
scored with a positive sign (+) post-fixed to the number. 
 
b) Toxicities: Toxicities to the treatment were assessed using RTOG 
Acute Morbidity Scoring Criteria and Common Toxicity Scoring 
Criteria Version 4.03. They were assessed before the initiation of 
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second course of radiotherapy and at the first month follow up after 
completion of radiotherapy course.  
 
c) Quality of Life (QoL): Quality of life was assessed in all treated 
patients at the first month follow up after treatment completion using 
the patient rated questionnaire developed by the European 
Organization for Research and Treatment of Cancer (EORTC), 
quality of life Questionnaire – QLQ C30.It measures the Quality of 
Life on the basis Global Health Status (2 point), Functional Scale 
(15 point) and Symptom Scale (13 point). All symptoms scales were 
noted and scored however, symptoms specific to head and neck 
cancer were evaluated and analysed in detail. It was compared to the 
QoL scores assessed at the base line and the improvement in QoL 
was thus calculated. 
 
Formulae for assessment: 
 
 Raw score: RS = (I1 + I2 + I3 +…+ In) 
        n 
 Here, I1, I2, I3,…In are the items included in a scale of 
assessment. 
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 Functional Scales:  S=       x 100 
       
Symptom Scales/ items:  S=     x 100 
 
 
 Global Health Status: S=     x 100 
 
 Range is the difference between the maximum and minimum 
possible value of raw score. The questionnaire is has been so designed 
that all items of any scale take the same range of values thus, range of 
raw score being the range of individual values.  
 
d) Response Assessment: Treatment response was assessed at the first 
month follow up after the end of radiation treatment using the 
RECIST (Response Evaluation Criteria in Solid Tumours) version 
1.1 for primary as well as nodal disease. Primary disease was 
assessed by clinical examination along with flexible endoscopy. 
Nodal disease was assessed by clinical examination. Overall 
response was assessed at the first month follow up with the help of 
imaging (Computed Tomography scans of the neck). 
1 – (RS – 1) 
     range 
 
(RS – 1) 
range 
 
(RS – 1) 
range 
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STATISTICAL ANALYSIS: 
 The statistical analysis and data computing was done using 
Microsoft® Excel™ 2013. Statistical ‘significance’ of the individual 
results could not be computed as the study was not powered enough. 
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RESULTS AND ANALYSIS: 
Out of the 30 patients treated, all were available for analysis. Results 
were analysed on the ‘Intention-to-treat’ basis. 
1. Age distribution (Table 1):  
The age groups of 51-70 constituted the majority of the study 
population.  
Age Groups Count Percentage Population 
31-40 3 10.00 
41-50 3 10.00 
51-60 9 30.00 
61-70 15 50.00 
 
 
2. Sex Distribution (Table 2): 
In our study group, population was largely male dominant, 
forming 73.3% of the total cases. 
Sex  Count Percentage Population 
Male 22 73.33 
Female 8 26.67 
  
 
 
Figure 2: Age Distribution 
 
 
 
 
Figure 3: Sex Distribution 
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3. Performance Status (Table 3):  
All the patients selected in this study had a performance status of 
3 or worse at presentation as measured by ECOG classification. 
Performance Status Count Percentage Population 
II 0 - 
III 20 66.67 
IV 10 33.33 
 
4. Staging: 
a. Stage Grouping (Table 4): 
Of the 30 patients, 13 belonged to locally advanced stage while 
17 patients belonged to the very advanced stage. 
Stage Grouping Count Percentage Population 
IV A 13 43.33 
IV B 17 56.67 
 
 
 
 
 
Figure 4: Performance Status 
 
 
 
 
Figure 5:Stage Grouping 
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b. Nodal Stage at Presentation:  
Stage IV B comprised 56.67% of the population and N3 node 
(node size more than 6 cm) at presentation was seen in 46.67% of the 
cases (n=14). One patient had bilateral cervical lymphadenopathy of 7 
to 8 cm while one other patient had a neck node of 13 cm, measured in 
the longest axis. 
 
c. Stage Distribution (Table 5): 
The stage distribution of the study population was as follows: 
Stage Distribution  
Tumour/ 
Node 
N1 N2 N3 Total 
T2 0 3 3 6 
T3 0 0 3 3 
T4a 0 10 7 17 
T4b 2 1 1 4 
 
 
5. Histological Differentiation: Histological differentiation was well 
differentiated in 11 (36.67%), moderate in 16 (53.33%) and poorly 
differentiated squamous cell carcinoma in 3 (10%). 
 
 
Figure 6: Stage Distribution 
 
 
 
 
Figure 7: Symptoms at Presentation 
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6. Symptoms at Presentation (Table 6): 
Symptoms At 
Diagnosis 
Count Percentage Population 
Painful neck swelling 12 40.00 
Dysphagia 13 43.33 
Others (Tongue/ Cheek 
lesion/ Hoarseness) 
8 26.67 
 
More than one symptom at presentation was seen in 12 (40%) of 
the patients. 
 
7. Sites of Primary Tumour (Table 7): 
Sites Count Percentage Population 
Oral Cavity 8 26.67 
Oropharynx 10 33.33 
Larynx 4 13.33 
Hypopharynx 8 26.67 
 
 
 
 
Figure 8: Site of Primary Tumour 
 
 
 
 
Figure 9: Oral Cavity Sub-sites 
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a. Oral Cavity Sub-sites (Table 8): 
The oral cavity tumours consisted of anterior tongue and buccal 
mucosa with equal frequency. None of the cases had primary of the lip 
or floor of mouth. 
Oral Cavity Sub-sites Count Percentage Population 
Anterior Tongue 4 13.33 
Buccal Mucosa 4 13.33 
 
b. Oropharyngeal Sub-sites (Table 9): 
A wide variety of sub-sites were seen to be involved among the 
oropharyngeal primary tumours. However, base of tongue was the 
commonest sub – site, with a maximum of 20% patients of the total 
population. 
Oropharynx Sub-sites Count Percentage Population 
Base Of Tongue 6 20.00 
Tonsillar Fossa 2 6.67 
Vallecula 1 3.33 
Posterior Pharyngeal 
Wall 
1 3.33 
 
 
 
Figure 10: Oropharyngeal Sub-sites 
 
 
 
 
Figure 11: Hypopharyngeal Sub-sites 
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c. Laryngeal Sub-sites: 
All four cases of laryngeal primaries were originating from the 
supra-glottic sub-site of Aryepiglottic fold. Right and left AE fold 
having equal incidence. 
 
d. Hypopharyngeal Sub-sites (Table 10): 
Hypopharyngeal  Sub-
sites 
Count Percentage Population 
Pyriform Fossa 6 20.00 
Post Cricoid 1 3.33 
Posterior Pharyngeal 
Wall 
1 3.33 
 
Thus, Base of Tongue and Pyriform Fossa were the commonest 
sub- sites of primary tumour in this study. 
 
8. Reason for Palliative Policy (Table 11):  
Tumour stage alone was not the sole deciding factor for 
recruiting a patient under this protocol. Performance status, co-
morbidities, expected survival, socio-economic factors were all taken 
into consideration. 
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Reason for Palliative RT Policy Count 
Percentage 
Population 
Stage 12 40 
Performance Status 13 43.33 
Co-morbidities 5 16.67 
 
9. Feeding Procedures: 
Feeding procedures prior to initiation of radiotherapy are 
required in tumours of hypopharynx and oropharynx where the 
presenting symptoms are dysphagia. Otherwise, it can be inserted at 
symptom aggravation. In our study, nasogastric placement was required 
in 70% (n=21) of the patients at some point of treatment. 
 
10. Number of RT Courses: 
Twenty seven patients (90%) completed both the courses of 
radiation. That is, they achieved a BED of 56 Gy to the tumour. Out of 
the remaining 3, one defaulted for follow up after the first course, two 
had worsening of performance status along with aggravation of 
symptoms from co-morbidities and hence were deferred for the second 
course of radiation. 
 
 
 
 
Figure 12: Reason for Palliative Policy 
 
 
 
 
Figure 13: Symptom Change after First Radiation Course 
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11. Symptom Change after First Radiation Course (Table 12):  
At the end of first course of radiation, contrary to the expectation, 
a majority of the patients (36.67%) experienced symptom aggravation 
in the form of dysphagia, pain or oedema over the pre-existent swelling. 
The symptom aggravation was mainly due to super added radiation 
toxicity to the pre-existing symptomatic disease. 
Symptom Change after 
First Course Radiation  
Count Percentage Population 
-2 5 16.67 
-1 4 13.33 
0 4 13.33 
1+ 11 36.67 
2+ 5 16.67 
 
12. Toxicities out of First Radiation Course (Table 13): 
Mucositis and dermatitis were the commonest toxicities observed 
after the delivery of first course of high dose radiation. No grade 3 
toxicities of any kind were observed among any of the treated patients. 
Few cases experienced grade 1 to 2 laryngeal/ pharyngeal toxicities. 
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First Radiation 
Course Toxicity 
No of Patients 
Skin 
Toxicity 
Mucositis Laryngitis Pharyngitis 
No toxicity 0 13 21 15 
Grade 1 26 1 4 7 
Grade 2 3 15 4 7 
Grade 3 0 0 0 0 
 
 
13. Response out of First Radiation Course (Table 14): 
At the second week follow up, only a minimal response was 
observed in majority of the patients while 6 patients had a partial 
response. 
Response After First 
Course Radiation 
Count Percentage Population 
Minimal 18 60.00 
Partial 6 20.00 
Not Assessable 6 20.00 
 
 
 
 
 
Figure 14: Toxicities out of First Radiation Course 
 
 
 
 
Figure 15: Response out of First Radiation Course 
 
 
 
0
5
10
15
20
25
30
Skin
Toxicity
Mucositis Laryngitis Pharyngitis
N
o
 o
f 
P
at
ie
n
ts
Toxicities out of First Radiation Course
No toxicity
Grade 1
Grade 2
Grade 3
0
10
20
30
40
50
60
70
Minimal Partial
Response out of First Radiation Course
83 
 
14. Symptom Relief at First month Follow-up (Table 15): 
At first follow up after completion of treatment course, 73.33 % 
patients experienced symptomatic improvement. Three patients did not 
have any change in symptoms while two patients had symptom 
worsening post-treatment. 
Symptom Change At 
First Follow Up 
Count Percentage Population 
-2 10 33.33 
-1 12 40.00 
0 3 10.00 
1+ 2 6.67 
2+ 0 0.00 
 
 
15. Toxicities at First month Follow-up (Table 16): 
At the first follow up after completion of treatment, definite signs 
of treatment toxicity were observed in all patients. Majority of the 
patients had some form of grade 2 toxicity. Five patients also 
experienced grade 3 pharyngitis. 
 
 
 
Figure 16: Symptom Change at First Month Follow Up 
 
 
 
 
Figure 17: Toxicities at First Month Follow Up 
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Toxicity at First 
Month Follow Up 
No of Patients 
Skin 
Toxicity 
Mucositis Laryngitis Pharyngitis 
No toxicity 0 11 5 4 
Grade 1 4 5 8 3 
Grade 2 23 11 14 15 
Grade 3 0 0 0 5 
 
 
16. Response at First month Follow-up (Table 17): 
At the end of first month from treatment completion, partial 
response was seen in 80% of the cases. No complete responses were 
observed. Minimal residue was seen in three cases. 
 
Response At First Month 
Follow Up 
Count Percentage Population 
Minimal Residual Disease 3 10.00 
Partial 24 80.00 
 
 
 
Figure 18: Response at First Month Follow Up 
 
 
 
 
Figure 19: Global Health Status 
(Transformed Scores) 
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17. Quality of Life Scores: 
The quality of life scores were assessed using the EORTC QLQ-
30. It is a 30 point patient (self-scoring) questionnaire. It assesses 
Global health status with 2 points, Functional scores with 15 points 
and Symptom scale with 13 points. 
 
a. Global Health Status (Table 18): 
The median pre-treatment Global health status score was 33 
(observed range: 8 – 42). The possible data range can be from 0 – 100. 
Representing, zero as a very poor score and 100 as the best possible 
self-assessment of health status. The improvement after completion of 
treatment was observed as the post-treatment median Global Health 
scores was computed to be 67. The median improvement in scores was 
by 34. 
Pre- treatment 
Global Health 
Score 
Post treatment 
Global Health 
Score 
Improvement in 
Global Health 
Score 
Data Range 
33 67 34 0-100 
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b. Functional Scales (Table 19): 
The summated and raw scores of functional scales were 
calculated. The pre – treatment median summated score for the study 
group was 35 while raw score was 2. The summated score may vary 
from 15 – 60 while raw score has the range of 1 – 4. Higher the 
functional score, better is the quality of life. 
Functional Scores 
No of Patients (Pre-
treatment) 
No of Patients (Post-
treatment) 
<50 10 2 
51-60 11 9 
61-70 5 11 
>70 1 5 
 
Thus, an improvement was observed in the post – treatment 
functional scores, as number of patients getting higher scores 
increased. The median improvement observed was by a score of 7. 
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c. Symptom Scales: 
The symptoms assessed were fatigue, nausea & vomiting, pain, 
dyspnoea, insomnia, loss of appetite, constipation, diarrhoea and 
financial difficulties. The median pre – treatment scores for each 
were: 
i. Fatigue – 8 /12 
ii. Nausea/ Vomiting – 2 /8 
iii. Pain – 6 /8 
iv. Dyspnoea – 2 /4 
v. Insomnia – 2 /4 
vi. Loss of Appetite – 2 /4 
vii. Constipation – 1 /4 
viii. Diarrhoea – 1 /4 
ix. Financial Hardships – 3 /4 
The median raw score was 2 while median summated score was 
36. The summated score may vary from 13 – 52 while raw scores may 
vary from the 1 – 4. The median post – treatment summated score was 
28. Thus, the median improvement in symptom score was measured 
to be (-7). As the scores on the symptom scale decrease, the 
improvement is measured as negative. One patient had no change in 
 
 
Figure 20: Functional Scales 
(Transformed Scores) 
 
 
 
Figure 21: Symptom Scales 
(Transformed Scores) 
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scores while two patients had a positive improvement in symptom 
score indicating symptom progression post treatment. 
 
18. Response Duration:  
Median duration of response of the patients treated with this 
protocol was 2 months post-completion of treatment. Maximum 
response duration observed was 3 months. Progression was seen in 
local disease for 11 patients (36.67%), loco-regionally for 11 patients 
(36.67%) and regional progression in 6 (20%) cases. 
  
 
 
 
 
 
DISCUSSION 
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DISCUSSION 
  The standard of care for unresectable head and neck cancer is 
concurrent chemoradiation with radiotherapy given up to 70 Gy (2 Gy/ 
fraction) along with Cisplatin 100mg/ m2 on Day 1, 22 and 43. However, 
this treatment is applicable to young patients with an ECOG performance 
status of 0 – 2, good expected survival and whom the radical treatment is 
likely to achieve a cure. Patients not fulfilling these pre-requisites for a 
radical treatment are more likely to go for palliation. Due to absence of 
guidelines or evidence base for palliative regimen dose, schedules and 
fractionations, patients are treated largely on the basis of traditional 
individualised institutional protocols. 
 
  Thus, this study protocol was formulated to determine the 
efficacy and feasibility of split-course hypofractionated palliative radiation 
among our patient population. Overviewing the results, the primary 
objective and goals of this study can be said to be achieved. 
 
  Our study population showed demographic trend towards the 
higher age group. Median age was 61 years. Almost 80% of the population 
was above 50 years of age with 30% being above 60 years. This may be 
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explained on the basis that, co-morbidity was one of the selection criteria 
for palliative treatment. As the age progresses, the likelihood of developing 
medical co-morbidities such as diabetes mellitus, systemic hypertension, 
coronary artery disease, cardiac conduction defects, renal and hepatic 
insufficiency increases. 
 
  The study group showed male predominance with only 27% 
patients being females. This was expected as the incidence of cancer is 
more in males in our country as they are more frequently exposed to 
carcinogens while at work, from habits of tobacco smoking or chewing, the 
use of pan masala and other risk taking behaviours. Also, rural females are 
less likely to report/ be taken to a tertiary cancer facility for treatment in 
time. 
 
  ECOG performance status at presentation was grade 3 or worse 
in all patients, as part of the inclusion criteria. Grade 3 performance status 
was in 67% of the cases while rest had grade 4. The NCCN guidelines for 
head and neck cancer recommend that patients of advanced stage with a 
good performance status of 0-2 should be given a trial of concurrent 
chemoradiation and attempted for cure and residual disease if any, should 
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be salvaged with surgical approach. Performance status in many studies 
has shown a correlation with treatment tolerance and outcome, thus a 
radical approach is not justified in patients with a poor PS. 
 
  The study had 57% of the patients in very advanced (IV B) stage 
while rest were in locally advanced stage (IV A). The patients with IV A 
disease were solely recruited on the basis of their performance status or co-
morbidities. Among the 13 patients in stage IV A, three patients had stage 
T2N2 while 10 patients had stage T4aN2. All patients were deemed 
unresectable by the consultant surgical oncologist, during the institutional 
multi-disciplinary tumour board. Nodal stage of N3 was seen in 14 out of 
17 patients belonging to stage IV B. One patient with supraglottic primary 
at presentation had a matted nodal mass of 13 cm in the longest dimension, 
while one other patient with a T2 base of tongue lesion, had bilateral nodal 
masses of 7 - 8 cm. The remaining patients had unilateral nodal masses 
ranging from 6 - 9 cm. These results thus corroborate the fact that our 
patients present in very advanced stages that are not amenable for any 
definitive modalities of treatment. 
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  The different sites of primary tumours were oral cavity (27%), 
oropharynx (33%), larynx (13%) and hypopharynx (27%). Base of tongue 
(20%) and pyriform fossa (20%) were the commonest sub-sites of primary. 
It is known that base of tongue and pyriform fossa are among the sites of 
occult disease in head and neck cancer cases. Primary in these sub-sites 
can remain dormant for prolonged periods without much symptomatic 
manifestations. First symptoms at presentation in such cases is usually of 
bulky cervical nodal disease with occult primary. Only on detailed ENT 
examination and imaging, a primary is visualised at these sub-sites. Minor 
salivary glands, vallecula and nasopharynx are among the other sub-sites 
that can have a similar presentation. 
 
  Further, all laryngeal primaries were seen arising from the 
supraglottic structure, aryepiglottic fold. Supraglottis is the only part of 
larynx with richest lymphatic supply. The drainage is commonly seen into 
level II to level IV lymph nodes from tumours at this site while level Ib 
and level V being less common. The incidence of occult nodal disease can 
be seen in 16% of the cases at the time of elective neck dissection. Patients 
observed for a clinically negative neck eventually present with a positive 
nodal disease in 33% cases. [87, 88] 
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  As mentioned above, stage was not the only criteria for selecting 
cases for palliative treatment. Poor performance status was the deciding 
factor for palliative course in 43% of the cases while 17% had co-
morbidities such as renal insufficiency (2), long standing diabetes mellitus 
(2) and recent coronary event (1). 
 
  Histologically, all tumours were squamous cell carcinoma as per 
the inclusion criteria. Among them, majority were only moderately 
differentiated (53%) while 37% were well differentiated and 10% were 
poorly differentiated. Differentiation of a tumour has shown to have a 
definite relation to the treatment response. Poorly differentiated tumours 
show a good cytoreduction initially however, recurrences are frequent. 
Well differentiated tumours are known to have a lesser response to 
chemoradiation. As the cells are terminally differentiated, they are less 
likely to enter the cell cycle thus reducing the efficacy of chemotherapy 
and radiation. 
 
  Further, nutritional management was meticulously looked after in 
all cases. All patients who underwent a feeding procedure, received a 
nasogastric tube insertion. Nine of the 30 cases were intervened with a 
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feeding procedure before initiation of any treatment in view of severe 
dysphagia or excessive pre-treatment weight loss. The remaining 12 out of 
21 cases received a feeding procedure during the course of treatment, 
mostly at the end of two week period. Dietary management was carried out 
for all patients. Those with feeding tube were given liquid to semi-liquid 
diet (chicken soups, raw eggs, kanji, milk, protein powder supplements, 
etc.) to compensate for the increased protein demand of cancer patients 
undergoing treatment. 
 
  Symptoms were recorded using the symptom assessment scale of 
0 to 4. Dysphagia was the prime symptom among most of the patients 
(43%). Grade 3 dysphagia was observed in 9 patients while 4 patients had 
only grade 1 to 2 dysphagia. Painful neck swelling was the next common 
symptom with 40% presenting with this symptom. The matted nodal mass 
with hypoxic and necrotic areas, skin infiltration and neural infiltration 
causing mass effect over cervical structures resulted in the patients 
presenting with pain. About 40% patients had more than one symptom at 
the time of presentation. 
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  After the first course of treatment, adequate symptom relief was 
observed in 30% of the patients. At least 37% of the cases had symptom 
worsening at the second week follow up after the first course. Symptom 
aggravation can be mainly attributed to the additive effect of radiation 
induced toxicities in pharynx or oral mucosa. Also, in patients with bulky 
cervical nodes, tumour lysis induced and vasogenic oedema post-
irradiation resulted in aggravation/ inappreciable reduction in the size of 
nodal disease. 
 
  No mucosal or laryngo-pharyngeal toxicity was seen for 13, 21 
and 15 number of patients respectively, of the patients treated. Commonest 
toxicity observed was grade 1-2 dermatitis and mucositis in 97% and 53% 
patients respectively. The first course of high dose radiation resulted in at 
least a minimal response in 60% of the tumours. Partial response was 
observed in 20% of the patients while disease status was not amenable for 
direct clinical assessment in 20%. 
 
  All patients received at least one course of radiotherapy. Only 
three patients could not be treated with the planned two courses of 
radiotherapy. One patient defaulted after the first course, while two 
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developed aggravation of symptoms from their co-morbidities and hence 
deferred from further treatment. No patient was deferred further course of 
treatment on grounds of tumour progression or excessive toxicity. 
 
  At the end of second course of treatment and the first month 
follow up, symptom relief was experienced by most of the patients (73%). 
Major improvement in symptom was noted in 33% while 40% experienced 
minor improvement. Only 7% (2 patients) had symptom worsening after 
the entire treatment course and 3 patients had no change in symptoms.  
 
  Toxicity profile was remarkable at the end of first month follow 
up. Skin toxicity of grade 1 – 2 was seen in all patients. Only 5 patients 
experienced a grade 3 pharyngitis. No other grade 3 toxicity was noted in 
any patient. No evidence of any toxicity in the mucosa, larynx and pharynx 
was noted in 11, 5 and 4 patients respectively. The improved toxicity 
profile was because of the 2 week gap period offered between the two 
courses of radiation. The gap allowed for normal tissue recovery which 
minimised the toxicity of the regimen. 
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  Response evaluation at the end of one month showed an overall 
response rates of 100% with only a minimal residual disease among 3 
patients. All the other patients achieved a partial response from this 
treatment regimen. The response was maintained for a median duration of 
2 months. Six patients were free from tumour progression for a period of 3 
months. 
 
  This study had a major advantage in the form of quality of life 
assessment and its comparison pre and post-treatment. The scores were 
assessed using a patient rated questionnaire, the EORTC QLQ-30. This 
questionnaire has a 30 point scoring system and has three elements 
namely, the Global health status, functional scales and symptom scales. 
Global health status has two items (questions) for assessment and the range 
of answers is 6, with a maximum score of 7 and minimum of one. 
Functional scales have 15 items (questions) for assessment with maximum 
score of 4 and minimum of one, thus the range of responses being three. 
Similarly, symptom scales assess for 13 items with maximum and 
minimum scores of 4 and 1. Range of symptom scales is 3. 
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  The pre – treatment Global health score was found to have a 
median of 33. With the maximum and minimum scores of 100 to 0, no 
patient had a score of more than 42. Hence, it is evident that all patients 
rated their overall state of health as poor at the time of presentation 
considering the presence of advanced disease which resulted in distressing 
symptoms and compromised the nutritional status. In the post – treatment 
assessment, the median score was found to be 67, thus giving a median 
improvement in overall health status by a score of 34. 
 
  Among the functional scales, the items assessed were for 
categories of physical functioning, role functioning, emotional, cognitive 
and social functioning. The median summated score was 35 (out of 60) 
while the median raw score (RS) and the median transformed score were 2 
(out of 4) and 56 (out of 100) respectively. The median scoring of 
individual categories was 14 (out of 20) for physical, 5 (out of 8) for role, 7 
(out of 16) for emotional, 4 (out of 8) for cognitive and 5 (out of 8) for 
social functions. Higher the summated score, more is the functional 
impairment thus, patients had a major compromise of their physical 
activity and the disease was responsible for a major emotional burden on 
their functioning. The cognitive and social abilities were largely 
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unaffected. The scores showed an improvement post – treatment with the 
median transformed score of 62. Maximum improvement was seen in 
physical and emotional functions as they showed low score at the time of 
presentation. 
 
  Symptom scales were scored for fatigue, nausea & vomiting, 
pain, dyspnoea, insomnia, loss of appetite, constipation, diarrhoea and 
financial difficulties. The median pre – treatment summated score was 27 
(out of 52) while the raw score and transformed score were 2 (out of 4) and 
36 (out of 100) respectively. The median scores of individual symptom 
categories were 8 (out of 12) for fatigue, 2 (out of 8) for nausea & 
vomiting, 6 (out of 8) for pain, 2 (out of 4) for dyspnoea, 2 (out of 4) for 
insomnia, 2 (out of 4) for loss of appetite, 2 (out of 4) for constipation, 2 
(out of 4) for diarrhoea and 3 (out of 4) for financial difficulties. Thus, 
financial burdens related to daily wages, cost of treatment and future 
financial issues of the family were largely worrisome for the patient. The 
patient rated quality of life symptom scale scores correlate well with the 
physician recorded symptom assessment scale at the time of presentation. 
Post – treatment, improvements were recorded in the pain scores and 
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fatigue scores. No major improvements were observed in the other scores 
as scored on the first month follow up. 
 
Overview of present study and available literature on palliative 
radiotherapy (Table 20) 
Author/ 
Reference 
Patient 
Characteristics 
Radiation 
Schedule 
Symptom 
control 
Treatment 
Response 
Toxicities 
Present 
Study 
30 Patients, 
Median age 61, 
PS >2 100%, 
Stage IV 100% 
2 courses 
of 20 Gy 
in 5 
fractions, 
2 week 
gap 
between 
courses 
Overall 
symptom 
improve-
ment 
73%, QoL 
improve-
ment 34% 
Overall 
Response 
rate 100%: 
Minimal 
residue in 
10%, PR 
80% 
G3 
pharyngi-
tis 16%, 
G2 
mucositis 
37%, G2 
laryngitis 
47% 
Agarwal 
et al [45] 
110 Patients, 
Median age 55, 
Stage IV 95% 
40 Gy in 
16 
fractions, 
further 10 
Gy if 
good 
response 
Less than 
50% in 
26%, 
more than 
75% in 
17% 
CR 10%, 
PR 63%, 
SD 16% 
G3 Skin 
14%, 
Mucositis 
G3 63%, 
G4 3% 
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Minatel et 
al [80] 
58 Patients, 
Median age 67, 
PS 60 (KPS), 
Stage IV 79% 
2 courses  
25 Gy/ 10 
fractions, 
2 weeks 
gap, with 
bleo-
mycin 
Overall 
symptom 
relief 81% 
CR 28%, 
PR 41%, 
SD 21%, 
PD 10% 
G3 
Mucositis 
46%, G3 
Dys-
phagia 
3.4% 
Mohanti 
et al [43] 
352 Patients, 
Median age 55, 
Stage IV 100% 
20 Gy in 5 
frac, 
further up 
to 70Gy if 
good 
response 
after 4 wk 
Pain 
>50% in 
57% Dys-
phagia 
>50% in 
53% 
At one 
month, 
37% PR 
At one 
month, 
100% 
patchy 
mucositis 
Corry et al 
[85] 
30 Patients, 
Median age 73, 
PS>2 66%, 
Stage IV 97% 
3 courses 
of 14 Gy 
in 4 
fractions, 
2 per day, 
4 week 
gap 
between 
courses 
Pain 56% 
Dys-
phagia 
33%, QoL 
improve-
ment 44% 
Overall 
response 
53% 
Grade 3 
mucositis 
0% 
Porceddu 
et al [82] 
35 Patients, 
Median age 68, 
PS>2 29%, 
Stage IV 65% 
30 Gy/ 5 
fractions, 
2 per 
week. 6 
Gy boost 
in selected 
patients 
Pain 67%, 
QoL 
improve-
ment 62% 
Overall 
response 
80% 
Grade 3 
mucosits 
26%, dys-
phagia 
11%, skin 
11% 
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Thus, the results of our study are similar to the studies available in 
literature over palliative head and neck cancer irradiation. A lower rate of 
acute toxicity along with an overall response rate of 100% are the added 
advantages noted in our study. 
 
Merits of the Study: 
a. Short, split – course of radiation was delivered, beneficial in a 
resource strained country and convenience of the patient 
b. Toxicities were meticulously watched for and incidence of grade 3 
toxicity was minimal. 
c. Two week gap allowed patient’s recovery 
d. Good symptom relief achieved 
e. Quality of Life scores improved adequately 
Kancherla 
et al [86] 
33 Patients, 
Median age 76, 
PS>2 58%, 
Stage IV 91% 
2 courses 
for total 
40 Gy in 
10 
fractions, 
2 week 
gap 
Overall 
response 
79% 
CR 39%, 
PR 33%, 
SD 21%, 
PD 6% 
Grade 3 
mucositis 
6%, skin 
3%, dys-
phagia 
9% 
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f. Response was observed for a good length of time without disease or 
symptom progression. 
g. Treated all the patients with poor performance status, very advanced 
stage of the disease or co-existing co-morbidities which are usually 
offered only best supportive care. 
 
De-Merits of the Study: 
a. Single arm, Phase II study 
b. Due to smaller sample size, significance of the results could not be 
derived. 
c. Long term follow up was not ensued, ergo late consequences of high 
dose radiation could not be commented upon. 
d. High dose of radiation itself caused initial symptom aggravation in a 
sizeable number of patients. 
 
Future Directions: 
a. Larger, multi-centric randomised controlled trial to prove the efficacy 
of this regimen over other palliative regimens in a diverse population of 
patients would be needed. 
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b. Long term follow up of patients to evaluate the late complications as 
well as to study the survival patterns and benefits. 
c. Establishing the patient related factors or selection criteria for 
differentiating patients suitable for palliative treatment from those 
amenable for radical approach. 
  
 
 
 
 
 
 
 
CONCLUSIONS 
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CONCLUSION 
 Thus, in the given scenario of Indian patient population of head and 
neck squamous cell carcinoma, where patients usually present in the locally 
advanced stages, the treatment plan depends largely on patient factors such as 
age, performance status, tumour extent and resectability and socio-economic 
factors. In patients having advanced age, poor performance status with 
advanced, unresectable cancer, cure is a distant reality and is rarely achievable 
even with all the recent developments in radiation technology or 
chemotherapeutic or targeted agents.  
 
This study hence achieved its objectives of showing that such patients 
are suitable for treatment under split-course hypofractionated radiotherapy. 
This regimen provided appropriate symptom relief (73% cases) and 
improvement in quality of life, with adequate tumour response maintained for 
a prolonged period along with manageable acute toxicities. 
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ANNEXURE - I 
RTOG CTCAE V4.03 
Grade  0 1 2 3 4 
Skin No 
change 
over 
baseline 
Follicular, 
faint or dull 
erythema/ 
epilation/dry 
desquamation/ 
decreased 
sweating 
Tender or 
bright 
erythema, 
patchy moist 
desquamation/ 
moderate 
edema 
Confluent, 
moist 
desquamation 
other than skin 
folds, pitting 
edema 
Ulceration, 
hemorrhage, 
necrosis 
Mucous 
Membrane 
No 
change 
over 
baseline 
Injection/ may 
experience 
mild pain not 
requiring 
analgesic 
Patchy 
mucositis 
which may 
produce an 
inflammatory 
serosanguinitis 
discharge/ may 
experience 
moderate pain 
requiring 
analgesia 
Confluent 
fibrinous 
mucositis/ 
may include 
severe pain 
requiring 
narcotic 
Ulceration, 
hemorrhage 
or necrosis 
Pharynx 
&Esophagus 
No 
change 
over 
baseline 
Mild 
dysphagia or 
odynophagia/ 
may require 
topical 
anesthetic or 
non-narcotic 
analgesics/ 
may require 
soft diet 
Moderate 
dysphagia or 
odynophagia/ 
may require 
narcotic 
analgesics/ may 
require puree or 
liquid diet 
Severe 
dysphagia or 
odynophagia 
with 
dehydration or 
weight 
loss(>15% 
from pre-
treatment 
baseline) 
requiring N-G 
feeding tube, 
I.V. fluids or 
hyper 
alimentation 
Complete 
obstruction, 
ulceration, 
perforation, 
fistula 
 
 
SALIVARY 
GLAND 
No 
change 
over 
baseline 
Mild mouth 
dryness/ 
slightly 
thickened 
saliva/ may 
have slightly 
altered taste 
such as 
metallic taste/ 
these changes 
not reflected 
in alteration in 
baseline 
feeding 
behavior, such 
as increased 
use of liquids 
with meals 
Moderate to 
complete 
dryness/ thick, 
sticky saliva/ 
markedly 
altered taste 
 Acute 
salivary 
gland 
necrosis 
 
Laryngitis 
No 
change 
over 
baseline 
Mild or 
intermittent 
hoarseness/ 
cough not 
requiring 
antitussive/ 
erythema of 
mucosa 
Persistent 
hoarseness but 
able to 
vocalize/ 
referred ear 
pain, sore 
throat, patchy 
fibrinous 
exudate or mild 
arytenoid 
edema not 
requiring 
narcotic/  
antitussive 
Whispered 
speech, throat 
pain or 
referred ear 
pain requiring 
narcotic/ 
confluent 
fibrinous 
exudate, 
marked 
arytenoid 
edema 
Marked 
dyspnea, 
stridor or 
hemoptysis 
with 
tracheostom
y or 
intubation 
necessary 
  
 
 
ANNEXURE - II 
Information to Participants 
Title: - “SPLIT-COURSE HYPOFRACTIONATED RADIOTHERAPY FOR PALLIATION OF 
ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA” 
PrincipalInvestigator: Dr. Vishal D Manik 
Name of Participant: 
Site:  Department of Radiotherapy, Madras Medical College & RGGGH, Chennai-3 
You are invited to take part in this research/ study/procedures/tests. The information in this 
document is meant to help you decide whether or not to take part. Please feel free to ask if 
you have any queries or concerns. 
What is the purpose of research? 
Head & neck cancer are one of the most common malignancy noted in our daily 
practice. Due to the insidious nature of the disease, many cases are unnoticed until they 
progress to advanced stage. Some of such advanced cases can be treated aggressively if 
the patient’s general condition permits or if patient is young, without co-morbidities. 
However those with poor general condition, depleted nutritional status, existing co-
morbidities or very advanced stage where curative intent is unrealistic, the usual 
treatment plan is palliation. Palliation is given either in form of radiotherapy, 
chemotherapy or best supportive care.Radiotherapy is the best modality available for 
palliation in head & neck malignancies. Limited evidence & guidelines are available 
regarding optimal dosage and fractionation in palliative setting for head & neck cancer 
sites. We want to test the efficacy of an altered treatment schedule in this disease. 
We have obtained permission from the Institutional Ethics Committee.  
The study design: Single arm Phase II Prospective study   
Study Procedures: The study involves evaluation of Advanced Head & Neck Squamous cell 
carcinoma treated with split-course hypofractionated therapy forwhich we will need, 
Chest X-ray, CECT Head & Neck, before & after treatment as part of standard protocol for 
any other patient receiving radiotherapy. At each visit, the study physician will examine 
you. Some blood tests will be carried out at first & second visit before each radiation 
course. 5ml of blood will be collected each time. Blood collection involves prick with a 
needle and syringe. These tests are essential to monitor your condition, and to assess the 
safety and efficacy of the treatment given to you. In addition, if you notice any physical or 
mental change(s), you must contact the persons listed at the end of the document.  
You may have to come to the hospital for examination and investigations apart from your 
scheduled visits, if required.  
 
 
Possible risks to you – None greater than standard patients receiving radiotherapy 
Possible benefits to you -  
Possible benefits to other people  
The results of the research may provide benefits to the society in terms of advancement 
of medical knowledge and/or therapeutic benefit to future patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical information 
(personal details, results of physical examinations, investigations, and your medical 
history). By signing this document, you will be allowing the research team investigators, 
other study personnel, sponsors, Institutional Ethics Committee and any person or agency 
required by law like the Drug Controller General of India to view your data, if required.The 
information from this study, if published in scientific journals or presented at scientific 
meetings, will not reveal your identity. 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your medical care or 
your relationship with the investigator or the institution. You will be taken care of and you 
will not lose any benefits to which you are entitled.  
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to withdraw 
from this study at any time during the course of the study without giving any reasons. 
However, it is advisable that you talk to the research team prior to stopping the 
treatment/discontinuing of procedures etc. 
 
Signature of Investigator                                                                   Signature of Participant   
Date                                                                                                      Date 
 
 
ANNEXURE - III 
INFORMED CONSENT FORM 
TITLE OF THE STUDY: “SPLIT-COURSE HYPOFRACTIONATED RADIOTHERAPY FOR 
PALLIATION OF ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA” 
NAME OF THE PARTICIPANT: 
NAME OF THE PRINCIPAL (Co – Investigator) : DR. Vishal D Manik 
NAME OF THE INSTITUTION: MADRAS MEDICAL COLLEGE 
I,_____________________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been answered. I am over 
18 years of age and, exercising my free power of choice, hereby give my consent to be 
included as a participant in “SPLIT-COURSE HYPOFRACTIONATED RADIOTHERAPY FOR 
PALLIATION OF ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA” 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me and about the nature of the study. 
3. I have been explained about my rights and responsibilities by the investigator. 
4. I have informed the investigator of all the treatments I am taking or have taken in the 
past 12 months including any native (alternative) treatment. 
5. I have been advised about the risks associated with my participation in this study.* 
6. I agree to cooperate with the investigator and I will inform him/her immediately if I 
suffer unusual symptoms. * 
7. I have not participated in any research study within the past 12 month(s). * 
8. I am aware of the fact that I can opt out of the study at any time without having to give 
any reason and this will not affect my future treatment in this hospital. * 
9. I am also aware that the investigator may terminate my participation in the study at 
any time, for any reason, without my consent. * 
10. I hereby give permission to the investigators to release the information obtained from 
me as result of participation in this study to the sponsors, regulatory authorities, Govt. 
agencies, and IEC. I understand that they are publicly presented. 
11. I understand that my identity will be kept confidential if my data are publicly 
presented 
12. I have had my questions answered to my satisfaction. 
13. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. 
By signing this consent form I attest that the information given in this document has been 
clearly explained and understood by me, I will be given a copy of this consent document 
Name and signature / thumb impression of the participant 
Name ________________ Signature_________________ Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name ________________ Signature_________________ Date________________ 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name ________________ Signature_________________ Date________________ 
 
 
ANNEXURE - IV 
ஆராய்ச்சி தகவல் தாள் 
 
சென்னை இராஜீவ்காந்தி ௮ரசு ச ாது ம௫த்துவமனைக்கு வரும் புற்று 
ந ாயாளிகளிடம்கதிர்வீச்சுசிகிச்னெப் ற்றிய ஆராய்ச்சி. 
 
            தனை மற்றும் கழுத்து  குதியில் முற்றிய புற்றுந ாய்க்கு  ை 
வனகயாை கதிர்வீச்சு சிகிச்னெ முனைகள் ௨ள்ளை.௮வற்றுள் 
குணப் டுத்த முடியாத மிகவும் முற்றிய புற்றுந ாய்க்கு முதலில்  ஒரு 
வாரத்திற்கு தீவிர கதிர்வீச்சு சிகிச்னெ ௮ளித்த பிைகு இரண்டு வாரங்கள் 
கழித்து மீண்டும் ஒரு வாரத்திற்கு தீவிர கதிர்வீச்சு சிகிச்னெ ௮ளித்து 
புற்றுந ாயின் தீவிரத்னத குனைப் து  ற்றி ஆராய்வது இந்த 
ஆராய்ச்சியின் ந ாக்கம். 
 
           நீங்களும் இந்த ஆராய்ச்சியில் ங்நகற்க  விரும்புகிநைாம்.இந்த 
ஆராய்ச்சியில் தீவிர  கதிர்வீச்சு சிகிச்னெ ௮ளித்து சிை சிைப்பு  
 ரிநொதனைக்கு ௨ட் டுத்தி ௮தன் தகவல்கனள 
ஆராய்நவாம்.இதைால் தங்கள்  
ந ாயின்ஆய்வறிக்னகநயாசிகிச்னெநயா ாதிப்பு  எற் டாது என் னத  
சதரிவித்துக்சகாள்கிநைாம். 
 
           முடிவுகனள ௮ல்ைது கருத்துகனள சவளியிடும் ந ாநதா ௮ல்ைது 
ஆராய்ச்சியின்ந ாநதா தங்களின் ச யனரநயா ௮ல்ைது 
௮னடயாளங்கனளநயா சவளியிட மாட்நடாம் ௭ன் னதயும் 
சதரிவித்துக்சகாள்கிநைாம். 
           இந்த சிைப்பு  ரிநொதனைகளின்முடிவுகனளயும்ந ாயின் 
தன்னம  ற்றியும் ஆராய்ச்சியின்முடிவின்ந ாது தங்களுக்கு 
௮றிவிப்ந ாம் ௭ன் னதயும் சதரிவித்துக்சகாள்கிநைாம். 
 
 
 
______________________________  ___________________________  
ஆராய்ச்சியாளர் னகசயாப் ம்     ங்நகற் ாளர்  னகசயாப் ம்
  
 
நததி:      நததி: 
 
 
     ANNEXURE - V 
ஆராய்ச்சி ஒப்புதல்  கடிதம் 
 
தனை மற்றும் கழுத்து  குதியில் மிகவும் முற்றிய புற்றுந ாய்க்கு 
ஒரு வாரத்திற்கு தீவிர கதிர்வீச்சு சிகிச்னெ ௮ளித்த பிைகு இரண்டு 
வாரங்கள் கழித்து மீண்டும் ஒரு வாரத்திற்கு தீவிர கதிர்வீச்சு சிகிச்னெ 
௮ளித்து செய்யப் டும் ஆய்வு. 
 
ச யர்:      நததி: 
 
வயது:      ௨ள்/புை ந ாயாளி எண்: 
 
 ால்:       ஆராய்ச்சி நெர்க்னக எண்: 
 
 இந்த ஆராய்ச்சியின்விவரங்களும் ௮தன் ந ாக்கங்களும் முழுனமயாக 
௭ைக்கு விளக்கப் ட்டை. 
 ௭ைக்கு விளக்கப் ட்ட விவரங்கனள  ான் புரிந்துசகாண்டு ௭ைது 
ெம்மதத்னத சதரிவிக்கிநைன். 
 ௭ைக்கு புற்றுந ாய் இருக்கும்  குதியில் கதிர்வீச்சு சிகிச்னெ செய்து 
சகாள்ள ெம்மதம். 
 இந்த ஆராய்ச்சியில் பிைரின்நிர்ப் ந்தமின்றி ௭ன் சொந்த விருப் த்தின் 
ந ரில்  ங்கு ச றுகிநைன்.இந்த ஆராய்ச்சியில் இருந்து  ான் ௭ந்ந ரமும் 
பின்வாங்கைாம் ௭ன் னதயும் ௮தைால் ௭ந்த  ாதிப்பும் ஏற் டாது ௭ன் னதயும் 
 ான் புரிந்து சகாண்நடன். 
  ான் தனை மற்றும் கழுத்து  குதியில் முற்றிய புற்று ந ாய் குறித்த இந்த 
ஆய்வுக்காை விவரங்கள் சகாண்ட தகவல் தானளப்ச ற்றுக்சகாண்நடன். 
 ௭ைக்கு இந்த ஆராய்ச்சியில் தீவிர கதிர்வீச்சு சிகிச்னெ ச ற்றுக் சகாள்ள 
ெம்மதம். 
 இந்த ஆராய்ச்சியிைால் ஏற் டும்  ன்னமகனளயும், சிை 
 க்கவினளவுகனளயும்  ற்றி சதளிவாக மருத்துவர்  மூைம் சதரிந்து 
சகாண்நடன். 
  ான் ௭ன்னுனடய சுயநினைவுடனும் மற்றும் முழு சுதந்திரத்துடனும் 
இந்த மருத்துவ ஆராய்ச்சியில் ௭ன்னை நெர்த்துக் சகாள்ள ெம்மதம் 
சதரிவிக்கிநைன்.   
        
         னகசயாப் ம் 
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